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ABSTRACT	
Due	 to	 the	 emergence	 of	multidrug	 resistant	bacteria,	bacterial	 infections	are	still	a	major	healthcare	problem.	Many	 factors	have	 led	 to	a	discovery	void	of	new	antibacterial	agents,	 rendering	 the	current	antibiotic	pipeline	inadequate	for	future	medical	needs.	For	example,	the	outcomes	from	pure	biochemical	high-throughput	screening	 (HTS)	assays	have,	 in	many	cases,	not	led	to	successful	clinical	compounds.	Therefore	cell-based	assays	might	be	 a	better	 choice	 for	primary	 screening.	However,	 the	 antibacterial	 cell-based	 assays	 in	 the	 current	 use	 often	 require	 long	 incubation	 times	 and	they	are	not	always	amenable	for	miniaturization	and	automation	for	HTS.	In	this	work,	two	screening	assays	based	on	recombinant	bioluminescent	E.	
coli	strains	were	optimized	and	 implemented	 in	 the	screening	of	chemical	libraries	 and	natural	products	 in	 antibacterial	drug	discovery.	One	of	 the	recombinant	 bacterial	 strains	 was	 a	 strain	 which	 is	 sensitive	 towards	transcriptional	and	translational	 inhibitors.	The	assay	based	on	 this	strain	was	 successfully	 miniaturized	 into	 384-format	 using	 automatized	 liquid	handling	 and	 was	 validated	 with	 a	 proof-of-concept	 library	 containing	known	 drugs.	 This	 provided	 a	 means	 to	 perform	 a	 larger	 scale	 high	throughput	screen	of	a	compound	library.	Based	on	the	HTS	hit	structures,	a	ligand-based	 in	silico	screening	of	a	virtual	chemical	 library	was	employed	for	 hit	 enrichment.	 The	 most	 active	 hits	 and	 the	 in	 silico	 selected	compounds	were	further	investigated	in	more	detail.		Natural	 products	 have	 been	 an	 important	 source	 in	 drug	 discovery,	especially	in	the	discovery	of	antibiotics	in	the	current	use.	However,	matrix	effects	such	as	colour	or	turbidity	of	natural	product	extracts	can	potentially	cause	 interference	 in	 conventional	 absorbance	 based	 microbial	 growth	inhibition	 assays.	 Also,	 conventional	 antibacterial	 assays	 are	 usually	 not	sensitive	 enough	 for	 detecting	 very	 small	 concentrations	 in	 fractionated	natural	 product	 extracts.	 The	 feasibility	 of	 bioreporter-based	 assays	 in	antimicrobial	screening	of	natural	products	was	demonstrated	by	screening	an	 in-house	 natural	 product	 library.	 One	 of	 the	 assays	 was	 also	implemented	 for	 investigating	 the	 antibacterial	 properties	 of	 an	 extract	
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from	 a	 fungal	 culture	 filtrate,	 which	 demonstrated	 the	 sensitivity	 of	 the	assay	for	identification	of	active	components	from	fractionated	samples.	In	 conclusion,	 sensitive	 and	 reproducible	 bioassays	 amenable	 for	 further	miniaturization	 and	 automation	 were	 developed	 for	 antibacterial	 drug	discovery.	Compared	to	conventional	antimicrobial	testing,	the	bioreporter-based	methods	 offer	 important	 improvements	 such	 as	 simultaneous	 data	acquirement	on	antimicrobial	activity,	first	indication	of	mode	of	action	and	significant	reduction	of	assay	 time	 to	2-4	h	compared	 to	24	h	 in	standard	susceptibility	 assays.	 The	 developed	 bioluminescent	 assays	 led	 to	 the	improvement	 of	 compound	 throughput	 in	 antimicrobial	 screening:	 from	hundreds	of	samples	 (natural	product	extracts	and	 fractions)	 in	manually	performed	 assays	 in	 96-well	 plates,	 to	 thousands	 of	 test	 compounds	(synthetic	compound	 libraries)	 in	384-well	 format	using	automated	 liquid	handling.	
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ABBREVIATIONS	
ATCC	 American	Type	Culture	Collection	CFU	 colony	forming	unit	CLSI	 Clinical	and	Laboratory	Standards	Institute			CRE	 carbapenem-resistant	enterobacteriaceae		CTX-M	 cefotaxime	hydrolyzing	capability	DMSO		 dimethyl	sulfoxide		
E.	coli	 Escherichia	coli	ESBL	 extended	spectrum	β-lactamase		HCS	 high	content	screening	HGT	 horizontal	gene	transfer		HPLC	 high-performance	liquid	chromatography	HTS	 high-throughput	screening	IC50		 concentration	giving	50	%	inhibition	IMP	 imipenem	IND	 investigational	new	drug	MDR	 multi-drug	resistant		MIC		 minimum	inhibitory	concentration	MRSA	 methicillin-resistant	S.aureus	MW	 molecular	weight	NCE		 new	chemical	entity	NDA	 new	drug/marketing	authorization	NDM-1	 New	Delhi	metallo-β-lactamase	1	NMR	 nuclear	magnetic	resonance	spectroscopy	NP	 natural	product	PBP	 penicillin-binding	protein	PDR	 Pan-drug	resistant	
S.	aureus		 Staphylococcus	aureus	S/B	 signal	to	background	S/N	 signal	to	noise	SD	 standard	deviation	SVH	 sulfhydryl	variable	TEM		 Temoneira		VIM	 Verona	integron-encoded	metallo-β-lactamase	VRE		 vancomycin-resistant	enterococci		VRSA	 vancomycin-resistant	S.	aureus	XDR	 extremely	drug	resistant	
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1. INTRODUCTION	
The	resistance	towards	antibiotics	in	current	use	is	a	growing	problem.	An	alarming	 fact	 is	 the	 emerging	 of	 multi-drug	 resistant	 bacterial	 strains	(MDR).	 Unfortunately,	 the	 drug	 discovery	 and	 development	 of	 novel	antibiotics	is	lagging	behind	and	the	discovery	of	compounds	for	the	future	antibiotic	 pipeline	 is	 decreasing.	 The	 inadequate	 discovery	 and	development	of	novel	antimicrobials	 is	of	great	concern	and	represents	an	unmet	medical	need	(Theuretzbacher	2012;	Golenser	and	Hunt	2013).	The	 standard	 antimicrobial	 susceptibility	 testing	 methods	 are	 quite	laborious	 and	 time-consuming,	 since	 the	 incubation	 times	 for	 bacterial	growth	 are	 long	 (24	 h	 or	 longer)	 and	 the	 throughput	 is	 limited.	As	high-throughput	screening	(HTS)	is	one	of	the	first	approaches	 in	the	 industrial	drug	discovery	process,	the	standard	antimicrobial	methods	are	not	always	suitable	for	HTS	purposes	because	the	assays	for	large	scale	screens	need	to	be	simple,	inexpensive,	rapid	and	amenable	for	miniaturization.		Furthermore,	 the	 most	 commonly	 used	 cell-based	 antibacterial	 methods	rely	on	reporting	bacterial	growth	or	viability	without	giving	any	indication	of	 a	 possible	 mechanism	 of	 action.	 Although	 target-based	 biochemical	assays	 are	 more	 easily	 adaptable	 to	 HTS,	 cell-based	 assays	 are	 more	biologically	 relevant,	 including	 also	 for	 example	 the	 evaluation	 of	 the	membrane	penetrating	abilities	of	the	compounds.	Phenotypic	screens	have	been	shown	to	be	successful	tools	in	drug	discovery	(Swinney	and	Anthony	2011;	 Zheng	 et	 al	 2013).	 Thus,	 a	 cell-based	 assays	 in	 high-throughput	format,	reporting	the	mechanism	of	action	at	the	early	screening	phase	is	an	advantageous	approach	for	enhancing	antibacterial	drug	discovery.	The	 assays	 should	preferably	be	 robust,	 sensitive,	 reproducible,	 time	 and	cost	saving	as	well	as	amenable	for	miniaturization	and	automation	for	HTS	(Macarron	 and	Hertzberg	2011;	 Janzen	2014).	Bioluminescence	detection	methods	can	offer	advantages	over	conventional	methods,	since	the	assays	
Introduction	
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are	cost-effective,	fast	and	sensitive	utilizing	small-volume	samples,	making	it	suitable	for	HTS.	The	studies	in	this	thesis	aimed	to	develop	and	implement	cell-based	assays	based	on	recombinant	bioluminescent	bacterial	strains	in	antibacterial	HTS.	Natural	products	are	an	excellent	source	 for	bioactive	compounds	serving	as	 inspirational	 molecules	 which	 can	 be	 modified	 and/or	 further	synthesized	 to	 become	 a	 lead	 compound	 in	 drug	 discovery.	 Here,	 this	approach	 was	 also	 addressed	 to	 assess	 the	 feasibility	 of	 the	 assays	 in	natural	product	extract	screening.	In	 this	 thesis,	 an	 overview	 over	 the	 drug	 discovery	 process	 is	 first	presented,	 followed	 by	 sections	 focusing	 on	 antibacterial	 drug	 discovery.	These	 sections	 provide	 an	 overview	 of	 antibiotic	 classes	 and	 the	 current	state	 and	 challenges	 of	 antibacterial	 drug	 discovery.	Thereafter	 the	main	results	of	studies	(I-IV)	are	presented	followed	by	a	general	discussion.
Review	of	the	literature	
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2. REVIEW	OF	THE	LITERATURE	
2.1. Overview	of	Drug	Discovery	And	Development	The	research	and	development	of	a	drug	from	project	start	to	drug	approval	is	a	long	process,	including	several	complex	phases	(Fig.	1),	which	can	take	10	to	15	years	for	one	single	drug	(Hughes	et	al.,	2011;	Moors	et	al.,	2014).	Moreover,	 the	 drug	 discovery	 and	 development	 process	 is	 extremely	expensive;	according	to	the	latest	estimate,	the	cost	per	drug	molecule	is	in	average	US$	2.6	billion	(Mullard	2014).	
Figure 1. Overview of the drug development process. Basic research is mostly carried
out in the academic institutions. The following phases are focused to the pharmaceutical
industry, although academic institutions have started to be more involved in pre-clinical
drug discovery and development phases (Figure is modified from Loregian and Palu
2013, and Silber 2010).Basic	 research	 of	 diseases,	 including	 target	 finding	 and	 validation,	 is	 the	foundation	 for	 the	 need	 and	 development	 of	 a	 medicinal	 product.	 The	search	 for	a	molecule	giving	a	desirable	biological	 response	related	 to	 the	disease	is	initiated	in	the	screening	and	lead	discovery	phases	(discussed	in	detail	 in	sections	2.2	and	2.4).	Pre-clinical	development	entails	rigorous	 in	
vitro	 research	 and	 in	 vivo	 animal	 studies	 in	 different	 areas,	 leading	 to	clinical	candidate	compounds.	The	pre-clinical	data	of	the	compound	is	then	compiled	and	submitted	as	an	investigational	new	drug	(IND)	application	to	
a	 regulatory	 authority,	 before	 any	 clinical	 testing	 on	 humans	 can	 start	(Hughes	et	al.,	2011;	Lombardino	et	al.,	2004).	The	clinical	trials	before	drug	approval	and	marketing	are	divided	into	three	phases.	The	objective	of	the	clinical	trials	is	to	investigate	the	safety	and	efficacy	of	a	medicine	in	human	volunteers.	 In	 brief,	 the	 drug	 is	 given	 to	 a	 smaller	 group	 of	 healthy	
BASIC
RESEARCH
LEAD
DISCOVERY
PRE-CLINICAL
DEVELOPMENT
CLINCAL
TRIALS  I-III
DRUG
APPROVAL
IND application
NDA
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volunteers	 in	 phase	 one	 to	 assess	 the	 initial	 dose,	 safety	 and	 possible	adverse	events.	During	phase	 two,	 the	 trials	progress	 to	 a	 larger	group	of	several	 hundreds	 of	 voluntary	 patients,	 while	 phase	 three	 includes	thousands	of	patients	and	long-term	studies	lasting	up	to	a	few	years	(Silber	2010).	 If	 the	 clinical	 trials	 are	 successful,	 a	 new	 drug/marketing	authorization	application	(NDA)	can	be	filed.	After	the	drug	approval,	a	post	marketing	 surveillance	 study	 is	 conducted,	 lasting	 several	 years	 (Stocks	2013).	
2.2. The	Lead	Discovery	Process	The	 lead	discovery	process	can	be	further	divided	into	several	phases	(Fig.	2).	After	identification	of	a	disease	target,	the	assay	development	phase	for	drug	 discovery	 purposes	 is	 initiated	 (discussed	 further	 in	 section	 2.4.2).	Using	 the	developed	assays,	compound	 libraries	are	screened	 for	primary	active	molecules,	which	are	further	validated	 in	an	active-to-hit	stage.	HTS	is	often	used	in	the	initial	phase	in	drug	discovery	programs.	In	cases	where	there	 is	 a	 known	 target	 (enzyme	 with	 a	 known	 active	 site	 for	 example),	structure	based	drug	design	can	be	employed	to	engineer	candidates	with	a	molecular	structure	that	is	likely	to	bind	to	the	target	(Ou-Yang	et	al.	2012).	
Figure 2. The stages of the lead discovery process. The process involves
collaboration of different scientific disciplines; biosciences are important in the
development of biological assays and screening, cheminformatics can be applied to
improve process before, during and after screening and medicinal chemistry is essential
in structure-activity studies.	The	 hit-to-lead	 process	 includes	 not	 only	 further	 characterization	 of	biological	 activity	 but	 also	 investigations	 of	 other	 properties,	 including	compound	 physicochemical	 properties	 (e.g.	 molecular	 weight,	 solubility).	
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Lead
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The	 goal	 is	 to	 develop	 compounds	 with	 the	 most	 drug-like	 properties	(Hughes	 et	 al.,	 2011;	 Stocks	 2013).	 This	 process	 is	 mostly	 driven	 by	 the	well-known	rule	of	five	postulated	by	Lipinski	et	al	2001.	It	states	that	drug-like	 compounds	 have	 in	 common	 the	 following	 molecular	 properties;	MW<500	Da,	Log	P≤5,	≤5	H-bond	donors,	≤	10	H-bond	acceptors.	Additionally,	 preliminary	 in	 vitro	 evaluation	 of	 pharmacodynamic	 and	pharmacokinetic	properties	 is	 ideally	started	at	an	early	stage	 in	 the	drug	discovery	process.	After	 identification	of	 lead	 compound(s),	 the	 leads	 are	optimized	 to	 improve	 any	 deficiencies	 found	 (for	 example	 potency	 or	cytotoxicity)	 by	 structure-activity	 relationship	 studies.	 Lead	 compound	series	should	show	activity	and	selectivity	in	biological	and	pharmacological	screens,	and	all	collected	data	 is	therefore	evaluated	 in	order	 to	select	 the	best	 lead	 candidates	 for	 additional	 pre-clinical	 development	 to	 further	enhance	 the	 properties	needed	 for	 therapeutic	 use	 (Bleicher	 et	 al.,	 2003;	Hughes	et	al.,	2011).		
2.3. Antibacterial	Drug	Discovery	
2.3.1. Overview	of	Antibiotic	Classes	and	Their	Targets	Antibiotics	can	be	either	bactericidal	(cell-death	inducing)	or	bacteriostatic	(growth	 inhibitory)	 agents.	 Furthermore,	 an	 antibiotic	 can	 be	 defined	 to	have	either	a	broad-	or	a	narrow-spectrum	activity,	depending	on	the	range	of	 bacterial	 species	 it	 affects.	 Since	 these	 definitions	 are	 very	 basic,	antibiotics	 are	usually	 classified	based	on	 their	mechanism	of	 action	 into	different	 classes,	 and	 then	 further	 subcategorized	 based	 on	 structural	similarities.	 Antibiotic	 classes	 and	 selected	 subclasses	 are	 presented	 in	Table	1	(the	list	of	subclasses	is	more	comprehensive	than	presented	in	this	table).	 In	 some	 cases	 an	 antibiotic	 could	 be	 defined	 to	 belong	 to	 several	classes,	 and	 often	 the	 mechanism	 of	 action	 can	 be	 more	 complicated,	involving	 several	means	 that	ultimately	 leads	 to	 growth	 inhibition	or	 cell	death	(Kohanski	et	al.,	2010).		
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Table 1. Classification of antibiotics. Modified from Wong et al., 2012
Class and subclasses Bacterial target Drug example
Cell wall inhibitors
β-lactams Cell wall biosynthesis and PBPs Penicillin
Glycopeptides Cell wall biosynthesis Vancomycin
Lipopeptides Cell membrane Polymyxin B
Metabolic inhibitors
Sulfonamides Enzyme in folate synthesis Sulfamethoxazole
DNA/RNA inhibitors
Fluoroquinolones DNA topoisomerases II and IV Ciprofloxacin
Rifamycins RNA polymerase Rifampicin
Nitrofurans Binds DNA and induces cross-linking Nitrofurantoin
Protein synthesis inhibitors
Macrolides 50S ribosomal subunit Erythromycin
Phenicols 50S ribosomal subunit Chloramphenicol
Aminoglycosides 30S ribosomal subunit Streptomycin
Tetrayclines 30S ribosomal subunit Tetracycline
	
Cell	wall	and	membrane	inhibitors.	The	β-lactams	are	a	class	of	different	derivatives	 of	 penicillin,	 and	 are	 further	 categorized	 into	 four	 different	subclasses;	 penicillins,	 cephalosporins,	 carbapenems	 and	 monobactams.	The	β-lactam	antibiotics	inhibit	the	synthesis	of	the	bacterial	cell	wall.	One	of	the	constituents	of	the	cell	wall	is	a	peptidoglycan	(murein)	layer,	which	is	a	polymer	of	N-acetylglucosamine	and	N-acetylmuramic	acid.	All	β-lactam	derivatives	share	a	common	β-lactam	ring	substructure,	which	resembles	a	dipeptide	 included	 in	 the	 side	 chains	 of	 peptidoglycan	 subunits.	 The	structural	similarity	 leads	to	 inhibition	of	the	 linking	(transpeptidation)	of	the	 glycan	 subunits	 by	 β-lactam	 binding	 to	 penicillin-binding	 proteins	(PBPs),	 which	 are	 transpeptidases	 involved	 in	 peptidoglycan	 remodeling	(Kohanski	et	al.,	2010,	McDermott	et	al.,	2003).	Glycopeptide	 antibiotics	 are	 large	 molecules	 with	 similar	 principle,	although	 they	 bind	 to	 the	 actual	 dipeptide	 (D-Ala-D-Ala),	 blocking	 the	peptidoglycan	 transglycosylation	 and	 transpeptidation	 processes.	
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Lipopeptide	antibiotics	target	the	cell	membrane,	for	example	polymyxin	B	binds	to	lipopolysaccharide	found	on	membranes	of	gram-negative	bacteria,	leading	 to	 disruption	 of	 the	 cell	 membrane	 (Zavascki	 et	 al.,	 2007).	Daptomycin,	 a	 cyclic	 lipopeptide,	 targets	 gram-positive	 bacteria	 using	 a	calcium	 dependent	 mechanism	 causing	 membrane	 depolarization	 (Lynn	2007,	Beiras-Fernandez	et	al.,	2010).	
Metabolic	 inhibitors.	 Sulfonamides	 are	 classified	 as	 metabolic	 inhibitors	targeting	 tetrahydrofolic	acid	synthetic	pathway	 in	bacteria.	Sulfonamides	act	 as	 competitive	 inhibitors	 for	 the	 enzyme	 dihydropteroate	 synthetase,	since	 the	 compound	 structure	 is	 an	 analogue	 of	 the	 natural	 substrate	 p-aminobenzoic	acid.	Trimethoprim	is	usually	co-administered	together	with	sulfonamides,	since	it	also	blocks	the	folic	acid	pathway,	but	at	a	later	stage	(McDermott	et	al.,	2003).	
DNA/RNA	inhibitors.	The	processes	involved	in	the	replication	of	bacterial	DNA	 and	 mRNA	 transcription	 are	 targets	 of	 several	 antibiotics.	 The	quinolones	 and	 their	 newer	 derivatives	 fluoroquinolones	 target	 bacterial	DNA	topoisomerase	II	(DNA	gyrase)	and	topoisomerase	IV.	Topoisomerase	IV	is	the	primary	target	in	gram-positive	bacteria,	while	this	enzyme	is	the	secondary	 target	 (DNA	 gyrase	 being	 the	 first)	 in	 gram-negative	 bacteria.	The	 topoisomerases	are	essential	enzymes	 relieving	 the	stress	 induced	 in	DNA	 during	 replication,	 by	 introducing	 negative	 supercoils	 into	 closed	circular	DNA.	The	topoisomerase	type	II	enzymes	function	by	breaking	and	re-sealing	double	stranded	DNA.	Fluoroquinolones	exhibit	their	mechanism	by	 binding	 to	 the	 DNA-topoisomerase	 complex,	 resulting	 in	 a	 bigger	quinolone-topoisomerase-DNA	complex.	The	enzyme	is	still	able	to	make	a	break	 in	 the	DNA,	but	re-joining	of	DNA	strands	 is	 inhibited.	The	complex	causes	blockage	of	 the	replication	 forks	 leading	 to	 immediate	 inhibition	of	DNA	 replication.	 Inhibition	 of	DNA	 gyrase	 seems	 to	 induce	 a	more	 rapid	effect,	since	it	functions	before	the	replication	forks	(Hooper	2001;	Hawkey	2003;	 Drlica	 et	 al.,	 2008).	 Interestingly,	 the	 inhibition	 of	 replication	 is	responsible	for	the	bacteriostatic	effect,	however	a	higher	dose	is	needed	to	acquire	the	bactericidal	effect	and	the	mechanism	of	the	second	lethal	step	seems	to	be	more	complex.	The	cell	death	phase	is	believed	to	involve	many	pathways	 and	 mediators	 such	 as	 the	 SOS	 response,	 cell	 filamentation,	liberation	 of	 lethal	DNA	 breaks,	 DNA	 damage	 by	 reactive	 oxygen	 species	
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and	the	toxin	MazF	(Drlica	et	al.,	2008;	Cheng	et	al.,	2013).	Nitrofurans	are	a	class	 of	 compounds	 sharing	 a	 5-nitrofuran	 ring	 substructure.	 They	 are	classified	 as	DNA	damaging	 agents;	however	 their	detailed	mechanism	of	action	is	still	not	fully	elucidated	(Vass	et	al.,	2008;	Munoz-Davila	2014).	Bacterial	RNA	polymerase,	which	is	responsible	for	RNA	synthesis,	consists	of	 a	 core	 enzyme	 consisting	 of	 subunits	 α2ββ′ω,	 but	 for	 the	 initiation	 of	bacterial	transcription	an	additional	σ	subunit	is	also	needed	(Darst	2001).	Rifamycins,	 such	 as	 rifampicin	 inhibit	 the	 initiation	 of	 RNA	 synthesis	 by	binding	 to	 the	 RNA	 polymerase	 β-subunit	 (encoded	 by	 rpoB	 gene).	Rifamycins	 are	 bactericidal	 against	 gram-positive	 bacteria,	 although	bacteriostatic	 against	 gram-negatives.	This	 is	due	 to	 the	difference	 in	 cell	wall	 build	 up,	 leading	 to	 a	 reduced	 uptake	 of	 the	 drug	 among	 the	 gram-negative	strains	(Campbell	et	al.,	2001;	Kohanski	et	al.,	2010;	Floss	and	Yu	2005).	
Inhibitors	 of	 protein	 synthesis.	 	 The	 ribosome	 involved	 in	 protein	synthesis	 is	also	 a	common	 target	 among	antibiotics	 in	use.	The	bacterial	ribosome	 consists	 of	 a	 smaller	 30S	 subunit	 and	 a	 larger	 50S	 subunit.	Translation	 of	 mRNA	 into	 polypeptides	 is	 divided	 into	 three	 stages;	initiation,	elongation	and	termination,	using	three	different	ribosomal	tRNA	binding	 sites;	 the	 P	 (Peptidyl)-site,	 A	 (aminoacyl)-site	 and	 E	 (exit)-site.	Different	 antibiotics	 inhibit	 protein	 synthesis	 at	 different	 translational	stages	by	binding	to	different	targets.	For	example,	the	macrolide	subclass,	including	ketolides,	consist	of	compounds	that	bind	to	the	50S	subunit	(23	rRNA,	E-site),	 preventing	 the	 elongation	 phase,	 leading	 to	 dissociation	 of	short	peptide-tRNAs	 from	 the	 ribosome	 (Katz	and	Ashley	2005;	McCoy	et	al.,	 2011;),	 although	more	 recent	 research	 suggests	 that	 the	 inhibition	 of	peptide-bond	formation	might	be	the	main	mechanism	of	action	(Kannan	et	al.,	2014).	Phenicols	also	bind	to	the	 larger	ribosomal	subunit,	for	example	chloramphenicol	 binds	 to	 the	 50S	 ribosome,	 blocking	 the	 interaction	between	the	amino	acid	and	the	peptide	bond	forming	peptidyltransferase	(McCoy	et	al.,	2011). 	Aminoglycosides	 are	 a	 class	 of	 compounds	 with	 an	 aminocyclitol	 ring	containing	 amino	 sugars	 through	 glycosidic	 linkages.	This	 structure	 gives	the	 compounds	 cationic,	 polar	 and	 basic	 chemical	 properties,	 as	 a	 result	
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they	 are	 more	 active	 against	 gram-negative	 bacteria,	 since	 they	 bind	 to	negatively	charged	structures	on	the	outer	membranes	due	to	their	cationic	nature.	 Aminoglycosides	 bind	 to	 the	 16S	 rRNA	 on	 the	 smaller	 ribosomal	subunit.	 The	 binding	 of	 aminoglycosides	 to	 the	 ribosomes	 at	 the	 A-site	affects	 the	 proofreading	 process,	 resulting	 in	 misreading	 of	 mRNA	 and	incorporation	of	 incorrect	amino	acids	 (Magnet	and	Blanchard	2005;	 Jana	and	Deb	 2006).	Most	 ribosome	 targeting	 antibiotics	have	 a	bacteriostatic	effect,	 although	 they	 can	 be	 bactericidal	 in	 certain	 cases,	 such	 as	 the	aminoglycoside	 class,	of	which	most	 are	bactericidal.	The	 aminoglycoside	action	 is	 caused	 by	 the	 synergy	 of	 the	 blockage	 of	 the	 ribosome	 and	 the	resulting	 misfolded	 or	 incorrect	 proteins	 incorporated	 into	 membranes,	causing	 altered	 membrane	 permeability	 and	 cell	 death	 (Wilson	 2009;	Kohanski	et	al.,	2010).		Tetracyclines	 also	bind	 to	 the	 smaller	 ribosomal	 subunit,	but	 function	by	blocking	 the	 initial	binding	of	aminoacyl-tRNA	 to	 the	A-site.	This	subclass	has	 a	 linear	 tetracyclic	 nucleus	 backbone	 as	 a	 shared	 substructure.	Tetracyclines	are	broad	spectrum	antibiotics	acting	on	both	gram-negative	and	gram-positive	bacteria	(Chopra	and	Roberts	2001).	
2.3.2. Bacterial	Resistance	to	Antibiotics	
Molecular	 mechanisms.	 Not	 long	 after	 the	 introduction	 of	 the	 first	antibiotics	into	clinical	use,	bacterial	resistance	towards	them	was	noticed.	Bacteria	can	become	resistant	either	endogenously	(intrinsic	resistance)	or	exogenously	 (acquired	 resistance).	 Intrinsic	 resistance	 is	 the	 result	 of	 for	example	 increased	 efflux	 of	 antibiotics,	 decreased	 uptake	 of	 antibiotics,	overproduction	 of	 target	 or	 a	 change	 in	metabolic	 pathways.	 Since	 these	mechanisms	 are	 general	 and	 can	 affect	 several	 types	 of	 drugs,	 this	 often	gives	 rise	 to	 multidrug	 resistance.	 Acquired	 resistance	 mechanisms	 are	more	antibiotic	class	specific,	 including	special	efflux	pumps,	modification	of	 target,	 and	 inactivation	of	 the	 antibiotic	 itself	 (McDermott	 et	 al.,	 2003;	Silver	2011).	Antibiotic	 resistance	 can	occur	by	 random	mutations	 in	 the	bacterial	 genome.	 Exogenous	 antibiotic	 resistance	 genes	 can	 be	 acquired	from	 outer	 sources	 to	 bacteria	 through	 horizontal	 gene	 transfer	 (HGT),	which	can	occur	by	conjugation,	transduction,	or	transformation	of	mobile	genetic	 elements.	 Transduction	 of	 DNA	 is	 carried	 out	 via	 bacteriophages	
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while	 transformation	 entails	uptake	of	naked	DNA	 from	 the	 environment	(Alekshun	 and	 Levy	 2007;	 Andersson	 and	 Hughes	 2010).	 Bacterial	conjugation	involves	the	transfer	of	plasmids,	which	exist	separate	from	the	bacterial	chromosome.	A	bacterium	can	contain	multiple	plasmids,	usually	carrying	 non-essential	 genes,	 although	 useful	 for	 the	 bacteria	 in	 certain	situations,	 for	 example	 one	 or	more	 genes	 for	 antibacterial	 resistance	 or	genes	involved	in	virulence	(Bennett	2008).	Plasmid-mediated	acquirement	can	also	involve	DNA	transposons,	so	called	jumping	genes;	since	they	have	the	ability	to	move	from	one	place	to	another	(Clarke	2006).		An	 example	 of	 resistance	 due	 to	 target	 modifications	 is	 synthesis	 of	 a	different	terminal	dipeptide	in	peptidoglycan	(D-Ala-D-Lac	instead	of	D-Ala-D-Ala),	resulting	in	a	weak	binding	affinity	for	vancomycin	(McDermott	et	al	2003).	Resistance	to	rifamycins	is	due	to	a	mutation	in	a	specific	segment	in	the	 rpoB	gene,	 leading	 to	an	amino	acid	change	 in	 the	RNA	polymerase	 β	subunit	(Goldstein	2014).	Aminoglycoside	resistance	 is	mostly	contributed	by	inactivation	of	the	antibiotics	by	enzymatic	acetylation,	phosphorylation	and	adenylation	(Alekshun	and	Levy	2007).	The	resistance	against	β-lactam	antibiotics	can	emerge	by	several	mechanisms,	including	mutations	causing	alterations	in	the	PBPs	or	acquisition	of	new	forms	of	PBPs,	leading	to	PBPs	with	 diminished	 drug-binding	 affinities.	 Alternatively	 resistance	 can	 be	caused	 by	 production	 (encoded	 by	 endogenous	 chromosomal	 genes)	 or	acquisition	of	one	or	(plasmid-encoded)	multiple	enzymes	that	inactivate	β-lactam	antibiotics	(McDermott	et	al.,	2003).	These	enzymes	are	well-known	hydrolyzing	enzymes	called	β-lactamases,	which	can	be	divided	into	either	serine	 β-lactamases	 or	metallo-β-lactamases.	 The	 first	 β-lactamases	were	active	 against	 penicillins	 and	 their	 derivatives,	 however	 later	 emerged	extended	 β-lactamases	 (ESBL)	 mediated	 by	 plasmids	 resulted	 in	 the	resistance	to	a	broader	spectrum	of	β-lactam	antibiotics	(3rd	generation	of	cephalosporins).	 Carbapenemases	 are	 a	 class	 of	 enzymes	 inactivating	 all	types	of	β-lactam	antibiotics	(Pfeifer	et	al.,	2010;	Tang	et	al.,	2014).	
Nomenclature	 of	 resistance.	 The	 threat	 caused	 by	 bacteria	 that	 are	resistant	 to	 antimicrobial	 drugs	 is	 becoming	 more	 serious	 and	 more	prevalent.	 A	 growing	 concern	 is	 the	 emergence	 of	 multi-drug	 resistant	(MDR)	strains,	defined	as	“acquired	non-susceptibility	to	at	least	one	agent	in	three	or	more	antimicrobial	categories”.	The	growing	resistance	has	also	
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necessitated	 the	 introduction	 of	 a	 definition	 for	 extremely	 drug	 resistant	bacteria	(XDR),	meaning	that	XDR-bacteria	are	sensitive	to	only	one	or	two	antibacterial	categories.	A	pan-drug	resistant	bacterium	(PDR)	is	defined	as	being	 resistant	 to	all	agents	 in	all	antimicrobial	categories	 (Magiorakos	et	al.,	2012)		
	
Alarmingly	resistant	bacterial	species.	An	alarming	fact	is	that	antibiotic	resistant	bacteria	are	not	only	prevalent	in	clinical	settings	but	also	found	in	communities.	Multi-resistant	bacteria	 in	hospitals	are	a	concern	 to	patient	safety;	causing	mortalities	as	well	as	increasing	hospital	stay	and	healthcare	costs	(Fair	and	Tor	2014).	Some	examples	of	multi-resistant	gram-positive	bacteria	 are	 Staphylococcus	 aureus	 and	 bacteria	 belonging	 to	 the	 genus	
Enterococcus.	Methicillin-resistant	Staphylococcus	aureus	(MRSA),	resistant	to	methicillin	 and	 other	 β-lactam	 antibiotics,	 has	been	 present	 for	 a	 long	time;	 but	 it	 has	 mainly	 been	 a	 concern	 as	 hospital	 acquired	 forms	 (Rice	2009).	 Even	 though	 measures	 have	 been	 taken	 to	 keep	 MRSA	 infections	under	control,	it	is	still	considered	a	concern,	as	MRSA	has	also	appeared	as	community-acquired	 phenotypes.	 Additionally,	 as	 vancomycin	 has	 been	often	used	as	the	last	line	of	defense	against	MRSA	infections;	vancomycin-resistant	 S.	 aureus	 (VRSA)	 has	 emerged.	 The	 most	 alarming	 resistant	bacteria	 of	 the	 enterococci	 are	 vancomycin-resistant	 enterococci	 (VRE),	mostly	 contributed	 by	 Enterococcus	 faecium	 in	 healthcare-associated	infections	(Pendleton	et	al.,	2013;	Rossolini	et	al.,	2014).	
	Emerging	resistance	in	gram-negative	species	has	become	more	severe	and	is	 now	 considered	 a	 bigger	 threat	 compared	 to	 gram-positive	 resistant	bacteria	(Souli	et	al.,	2008,	Gagliotti	et	al.,	2011,	Rossolini	et	al	2014).	The	most	 concerning	 are	 the	 ESBL-producing	 enterobacteriaceae	 and	carbapenem-resistant	 enterobacteriaceae	 (CRE),	 mostly	 caused	 by	
Klebsiella	pneumoniae	and	Escherichia	coli.	Even	though	the	MDR	rates	in	K.	
pneumoniae	 are	 higher,	 E.	 coli	 is	 considered	 to	 have	 a	 larger	 clinical	relevance	 (Theuretzbacher	 2013).	 Besides	 normally	 residing	 in	 human	intestinal	 tracts,	E.	coli	can	 also	 cause	 urinary	 tract	 infections,	 foodborne	illnesses	and	severe	hospital-acquired	infections	(Fair	and	Tor	2014).	There	are	several	plasmid	encoded	ESBL	enzyme	types.	The	first	types	were	TEM	and	 SVH,	 the	 CTX-M	 type	 common	 in	 E.	coli	 evolved	 from	 these	 through	
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horizontal	 gene	 transfer	 (Ho	 et	 al.,	 2010).	 The	 most	 common	 metallo-β-lactamases	in	gram-negative	bacteria	are	of	VIM	and	IMP	type	(Pfeifer	et	al.,	2010).	 However,	 a	 new	 metallo-β-lactamase	 type	 (NDM-1)	 was	 recently	identified	in	K.	pneumoniae	(Yong	et	al.,	2009),	although	this	type	was	also	found	 later	 in	 E.coli	 (Poirel	 al.,	 2010;	 Pfeifer	 et	 al.,	 2011).	 Other	 gram-negative	 bacteria	 of	 importance	 due	 to	 resistance	 are	 Pseudomonas	
aeruginosa,	and	Acinetobacter	baumannii	(Fair	and	Tor	2014).	
2.3.3. Challenges	and	Current	Situation	The	most	common	antibiotics	still	used	today	were	discovered	in	the	1940-1960s,	in	the	so	called	golden	era	of	antibiotics.	The	antibiotics	introduced	after	 this	 era	 have	 been	 mostly	 derivatives	 of	 known	 structural	 classes	usually	 affecting	 the	 same	 molecular	 target.	 Due	 to	 the	 emerging	 multi-resistant	 bacterial	 strains,	 the	 current	 antibiotics	 have	 rapidly	 become	ineffective.	In	addition,	the	introduction	of	new	antibiotics	to	the	market	has	declined	 over	 the	 last	 thirty	 years	 (Table	 2)	 and	 therefore	 there	 is	 a	substantial	need	to	develop	novel	antibacterial	drugs.	
	
Table 2. The number of approved
new antibiotics 1980 - 2012. Based
on Butler et al., 2013; Bassetti et al.
2013.
Years Approved antibiotics
1980 - 1984 17
1985 - 1989 12
1990 - 1994 10
1995 - 1999 12
2000 - 2004 9
2005 - 2007 4
2008 - 2012 8
	
	The	 novelty	 factor	 in	 antibiotics	 can	 be	 defined	 in	 several	 ways;	 the	compounds	 affecting	 a	 known	 target	 can	 be	 improved	 to	 have	 a	 broader	spectrum,	 to	work	 on	 resistant	pathogens	 or	 alternatively	 to	 have	 better	physicochemical	 properties	 for	 safer	 and	 easier	 administration.	 Greater	
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novelty	 is	 found	 in	 compounds	 that	 affect	 a	 known	 target	 with	 a	 new	mechanism	of	 action	or	 compounds	with	 structures	not	described	before	affecting	a	completely	new	target,	although	the	latter	seem	to	be	extremely	challenging	in	current	antibacterial	discovery	(Gwynn	et	al	2010).		
	
	The	 current	 antibiotic	 pipeline	 is	 not	 adequate	 compared	 to	 the	 medical	need.	 Between	 the	 years	 2000	 and	 2012,	 only	 22	 antibiotics	 have	 been	approved,	of	which	no	more	than	5	are	first-in-class	antibiotics.	Some	of	the	recently	approved	agents,	for	example	daptomycin	(2003)	and	bedaquiline	(2012)	were	 actually	discovered	 already	 in	1986	 and	1997	 (Butler	 et	 al.,	2013;	Lewis	2013).	 Several	 societies	have	 recently	 recognized	 the	urgent	need	 for	 the	 discovery	 and	 development	 of	 new	 antibacterial	 drugs	(Infectious	 Diseases	 Society	 of	 America,	 2010;	 Freire-Moran	 et	 al.,	 2011;	Cars	et	al.,	2011).	Even	though	the	cumulative	amount	of	antibacterials	has	increased	over	the	years,	the	net	number	of	available	agents	for	therapeutic	use	 has	 declined	 due	 to	 the	 resistance	 issue	 and	 compounds	 failing	 in	clinical	 trials	 (Kinch	 et	 al.,	 2014).	 Especially	 the	 pipeline	 against	 gram-negative	bacteria	has	been	neglected	and,	although	some	progress	has	been	seen	recently,	the	agents	effective	against	gram-negative	bacteria	in	current	development	(clinical	phases),	are	 less	compared	to	gram-positive	bacteria	(Butler	et	al.,	2013;	Boucher	et	al.,	2013;	Page	and	Bush	2014).	
	The	 reasons	 for	 the	 decline	 in	 antibacterial	 drug	 discovery	 have	 been	debated	 to	 be	 the	 low	 investment	 return,	 underestimation	 of	 bacterial	resistance	and	the	thought	that	the	available	range	of	antibiotics	covers	the	medical	needs	for	all	bacterial	infections	(Lewis	2013).	The	older	antibiotics	were	discovered	by	empirical	screening,	without	knowing	the	full	detailed	mechanism	of	action,	which	was	not	sometimes	elucidated	until	 later.	The	introduction	 of	 the	 target-based	 screening	 approach,	 which	 has	 been	successful	 in	many	other	drug	discovery	 fields,	was	 also	 employed	 in	 the	infectious	disease	area	with	high	hopes	for	finding	new	antibacterial	agents.	However,	the	outcome	of	target	based	screens	was	not	as	high	as	expected	and	possible	reasons	 for	 this	have	been	up	 for	discussion.	The	 lack	of	hits	and	leads	in	a	screening	campaign	is	not	always	due	to	the	existing	assays,	but	it	also	reflects	the	insufficient	compound	source	available	for	screening.	
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At	the	same	time	as	target	based	screens	became	the	method	of	choice;	the	use	 of	 natural	 products	 as	 screening	 source	 was	 reduced.	 The	 screening	collections	used	for	antibacterial	screens	were	the	same	as	for	other	disease	areas,	 thus	 containing	 molecules	 targeted	 for	 diseases	 in	 human	 cells.	However,	targets	for	human	diseases	are	commonly	targets	associated	with	the	 mammalian	 cell	 membranes,	 such	 as	 receptors.	 Compounds	 for	mammalian	 intracellular	 targets	 might	 not	 either	 be	 successful,	 since	bacteria	have	structurally	different	cell	envelopes	compared	to	mammalian	cell-membranes,	 	 the	 compounds	 need	 to	 cross	 the	 bacterial	 cell	 wall	 to	reach	 intracellular	bacterial	targets.	As	the	gram-negative	cell	wall	 is	more	complex,	 the	 active	 compound	 needs	 to	 first	 cross	 an	 additional	 outer	membrane,	 compared	 to	 gram-positive	bacteria.	Another	 challenge	 in	 the	antibacterial	 discovery	 against	 gram-negative	 bacteria	 is	 the	 presence	 of	efflux	pumps	(Monaghan	and	Barrett	2006;	Silver	2011).	
	Interestingly,	the	antibacterial	agents	discovered	from	natural	sources	have	different	properties	 than	 other	 drugs,	 they	 are	 typically	 larger	 and	more	polar	compounds.	The	antibacterial	compounds	specific	for	gram-negatives	are	 however	 in	 general	 smaller	 in	 molecular	 weight	 and	 more	 polar	compared	 to	 antibacterials	 for	 gram-positive	bacteria	 (Lewis	2013;	 Singh	2014).	Compared	to	other	drugs,	the	achieved	blood	plasma	 levels	need	to	be	higher	 for	antimicrobials,	 leading	 to	higher	probabilities	of	cytotoxicity	in	 clinical	 use	 and	 reduced	 safety	 (Lewis	 2013).	 Unfulfilled	 expectations	from	 the	 target-based	 screens	 have	 led	 to	 renewed	 interest	 in	 cell-based	screens,	 especially	 mechanism-based	 screens	 that	 also	 combine	 a	 target-based	approach	in	a	biological	environment	(Gwynn	et	al.,	2010).	
	
2.3.4. Cell-Based	Antimicrobial	Screening:	Standard	and	
Contemporary	Methods	
Standard	Susceptibility	Methods.	There	are	several	standard	methods	in	current	 antimicrobial	 susceptibility	 testing	 such	 as	 the	disk	diffusion	 and	broth	 dilution	 methods.	 The	 disk	 diffusion	 test	 is	 based	 on	 small	 discs	containing	 a	 specific	antibiotic	or	 a	 test	sample	which	are	placed	onto	an	agar	plate	coated	with	bacteria.	The	plate	 is	 incubated	 for	18-24	h	at	35°-
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37°C,	and	the	plate	 is	then	visually	examined	to	determine	the	diameter	of	the	zone	of	inhibition	that	has	evolved	around	the	discs.		Susceptibility	 testing	 can	 also	 be	 performed	 in	 liquid	 cultures;	 the	 broth	macrodilution	method	is	performed	by	inoculating	tubes	with	1-2	ml	broth	with	bacteria	 and	different	 antibiotic/sample	 concentrations	 in	 each	 tube	and	allowed	to	 incubate	18-24	h.	Tubes	are	then	visually	examined	for	the	presence	 of	 bacterial	 growth.	 This	 test	 can	 also	 be	 performed	 in	 smaller	volumes	(100-200	µl)	in	96-well	microtiter	plates	and	is	then	referred	to	as	the	microdilution	method.	Analysis	 of	 results	 from	 96-well	 plates	 can	 be	performed	by	manual	inspection	or	by	measurement	of	turbidity.	The	main	aim	 of	 broth	 dilution	 methods	 is	 to	 determine	 the	 minimum	 inhibitory	concentration	 (MIC),	 which	 means	 the	 smallest	 concentration	 of	 an	antibiotic/sample	 that	 inhibits	 bacterial	 growth.	 However,	 standardized	susceptibility	 tests	 are	 used	 in	 clinical	 microbiology	 diagnostics	 and	 the	primary	purpose	is	to	detect	and	monitor	the	resistance	of	clinical	bacterial	isolates	 from	patients	 towards	antibiotics.	The	obtained	MIC	value	 is	also	used	 as	 a	 reference	 when	 evaluating	 the	 best	 antibiotic	 therapy	 for	 a	patient.	 International	 standards	 for	 breakpoint	 values	 regarding	susceptibility	of	different	antibiotics	to	different	pathogens	are	available	for	example	from	the	Clinical	and	Laboratory	Standards	Institute	(CLSI)	located	in	USA	(Jorgensen	and	Ferraro	1998	and	2009;	Wiegand	et	al.,	2008).			The	 methods	 intended	 for	 clinical	 microbiology	 are	 also	 used	 in	 the	discovery	of	antibacterial	agents	(Wiegand	et	al.,	2008).	These	methods	are	feasible	 when	 the	 amount	 of	 samples	 to	 be	 investigated	 is	 few,	 or	 for	confirmation	 of	 antibacterial	 activity.	 However,	 the	 methods	 described	above	are	quite	 laborious	and	time-consuming	and	these	methods	are	thus	not	 the	most	 suitable	 for	 antibacterial	HTS	 for	 large	 chemical	 libraries	 in	384-well	format	or	in	even	higher	density	plates.	
Assays	using	reporter	proteins.	There	have	been	several	studies	using	β-galactosidase	 in	 reporter-based	 antimicrobial	 screens.	 For	 example,	 a	reporter	 strain	 of	 Bacillus	 subtilis,	 containing	 β-galactosidase	 as	 reporter	protein	detected	by	fluorescence	caused	by	the	reporter	enzyme	activity	on	
a	substrate,	has	been	used	in	detecting	cell	wall	inhibitors	(De	Pascale	at	al.,	2007).	This	 approach	 has	 been	 recently	 updated	 for	 the	 use	 in	pathway-
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based	 screen	 of	 autolysis	 inducers	 in	 B.	 subtilis	 (Lacriola	 et	 al.,	 2013).	Bioreporter	 assays	 using	 luciferase	 as	 reporter	 protein	 is	 discussed	 in	section	2.5.3.	
Assays	with	other	setups.	An	example	of	a	newer	cell-based	method	is	the	resazurin	 assay,	 which	 is	 now	 also	 commonly	 used	 in	 antibacterial	screening.	 This	 method	 determines	 cell	 viability	 in	 an	 easy	 manner,	although	the	actual	assay	incubation	time	used	with	this	method	is	still	18–24	h	(Sarker	et	al.,	2007).		An	 industrial	scale	HTS	was	performed	using	an	approach	with	mutant	S.	
aureus	 strains,	 sensitized	 toward	 detecting	 inhibitors	 of	 the	 bacterial	mevalonate	 pathway,	 which	 is	 an	 important	 metabolic	 pathway.	 In	 the	sensitized	 strains,	 the	 genes	 for	 a	 specific	 enzyme	 involved	 the	 pathway	were	placed	under	an	IPTG	promoter.	The	assay	was	based	on	the	growth	of	the	 mutant	 strains	 in	 low	 IPTG	 concentration	 and	 bacterial	 density	 was	determined	by	absorbance	measurement	after	8	h	(Ferrand	et	al.,	2011).	
2.4. High-Throughput	Screening	HTS	 is	 a	 miniaturized	 and	 automated	 process	 by	 which	 thousands	 to	hundreds	of	thousands	of	compounds	can	be	screened	using	a	target-based	or	a	cell-based	assay,	typically	at	concentrations	ranging	between	1-50	µM,	and	 the	 final	 outputs	 of	HTS	 are	 termed	 hits	 (Kesurü	 and	Makara	 2006;	Martis	et	al.,	2011).	HTS	produces	often	a	vast	collection	of	compounds	that	show	the	activity	in	the	assay	used;	therefore	a	threshold	value	(often	50%)	for	the	activity	is	usually	set	to	yield	primary	hits,	which	need	re-testing	to	confirm	their	activity.		Follow-up	 screens	 include	 for	 example	 dose-response	 studies	 and	 other	compound	characterization	studies.	Orthogonal	assays	and	counter	screens	are	also	often	employed	to	 identify	false-positives,	 i.e.	compounds	that	are	assay	artifacts.	Target	selectivity	assays	can	be	employed	to	verify	that	the	hit	 is	not	affecting	other	 targets.	Orthogonal	assays	are	usually	performed	with	another	 target	or	another	detection	method	 than	 the	one	used	 in	 the	primary	screening	(Bleicher	et	al.,	2003;	Kesurü	and	Makara	2006;	Hughes	et	al.,	2011).		
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Important	factors	related	to	the	success	of	HTS	are	the	three	corner	stones;	the	 quality	 of	 the	 assay,	 costs	 and	 time	 (Fig.	 3).	 Regarding	 the	 clinical	success	of	a	drug	that	can	be	traced	back	to	a	 lead/hit	from	an	HT	screen,	other	 factors	 are	 also	 of	 importance.	 	 These	 factors	 include	 the	 clinical	relevance	of	the	assay	(target	relevance),	the	screening	 libraries	(diversity	and	 drug-likeness)	 as	 well	 as	 the	 phases	 of	 lead-to-drug	 development	(Macarron	et	al.,	2011;	Macarron	and	Hertzberg	2011).		
Figure 3. Important factors in HTS. The factors are all related, a change in one
condition can have an impact on the others (Modified from Mayr and Bojanic 2009)
2.4.1. Screening	Assays		
In	vitro	and	in	silico	assays.	The	choice	of	assay	for	HTS	is	determined	by	the	 type	 of	 activity	 that	 is	 of	 interest	 (inhibition	or	 activation	 of	 growth,	enzymes,	 proteins,	 cellular	 pathways,	 genetic	 expression	 etc.)	 and	 can	 be	either	 in	 vitro	 or	 in	 silico	 based.	 In	 vitro	 assays	 are	 further	 divided	 into	biochemical	 and	 cell-based.	 Biochemical	 screens	 are	 based	 on	 a	 known	isolated	target,	for	example	an	enzyme,	or	a	receptor	that	has	been	linked	to	
a	disease.	Usually	biochemical	screens	detect	compounds	that	interact	with	the	target;	either	a	change	in	the	target	itself,	or	detect	the	conversion	of	a	substrate	by	the	target.	Cell-based	assays	are	based	either	on	microbial	or	mammalian	cells	and	are	more	complex,	especially	imaging-based	methods.	
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Cell-based	assay	designs	can	be	further	categorized	into	second	messenger	assays,	 reporter	gene	assays,	or	cell	proliferation	 assays	 (Sundberg	2000;	Martis	et	al.;	2011).	Phenotypic	screening;	i.e.	the	use	of	assays	that	are	not	based	on	one	single	specific	target,	for	example	cell	proliferation	assays,	has	again	 gained	 popularity	 in	 modern	 drug	 discovery	 settings	 (Zheng	 et	 al.,	2013).		Using	a	phenotypic	assay	in	HTS	renders	the	standard	lead	discovery	phase	slightly	different,	as	a	 target	 identification	phase	will	be	 incorporated	 into	the	 process	 downstream	 of	 the	 hit	 identification	 screen.	 In	 cell-based	assays,	the	compounds	are	subjected	to	more	physiological	conditions,	such	as	 cell	 membranes,	 different	 proteins	 and	 cellular	 networks.	 Especially	phenotypic	 screens	 can	 identify	 compounds	 affecting	 different	 disease-related	targets	and	signaling	pathways	(Shenone	et	al.,	2013).	Virtual	or	in	silico	screening	refers	to	computational	techniques	and	can	be	further	 subdivided	 into	 structure-based	 or	 ligand-based	 methods.	Structure-based	methods	are	used	when	the	target	structure	is	known.	For	example,	molecules	 binding	 to	 a	 known	 active	 site	 in	 a	 protein	 structure	which	can	be	identified	by	docking-based	virtual	screening	or	alternatively	
de	 novo	 design	 (Ou-Yang	 et	 al.	 2012).	 In	 ligand-based	 screening,	 the	structures	of	known	bioactive	molecules	are	used	as	a	starting	point	for	the	search	 of	 similar	 compounds	 (2D	 or	 3D)	 or	 specific	 pharmacophores	 in	virtual	libraries	(Duffy	et	al.,	2012;	Sliwoski	et	al.,	2013).			
Assay	 detection	 technologies.	 	The	 detection	 technologies	 in	HTS	 assays	are	 commonly	 based	 on	 absorbance,	 scintillation,	 fluorescence,	 and	luminescence	 (Table	 3).	 Additionally,	 label-free	 methods	 (for	 example	mass-spectrometry	 or	 optical	 sensors)	 enabling	 direct	 measurement	 of	wanted	 analyte	 without	 any	 labeling	 or	 reporters,	 have	 become	 more	amenable	 for	 HTS	 purposes	 (Halai	 et	 al.,	 2012).	 Radiometric	 assays	 are	becoming	 less	 frequently	used,	but	still	 remain	 a	 good	 technique	 in	some	cases.	Fluorescence-based	methods	are	prevalent	in	screening	assays	due	to	high	 sensitivity	 (Sundberg	 2000;	 Inglese	 et	 al.,	 2007;	 Janzen	 2014).	However,	using	fluorescence	as	a	detection	method	in	screening	assays	also	has	some	drawbacks.	As	an	excitation	source	is	needed	for	photon	emission,	the	 existing	 background	 signal	 in	 an	 assay	 based	 on	 direct	 fluorescence	
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measurements	of	reporters	can	be	quite	high.	The	background	signal	 is	an	important	 factor	 in	HTS	 assay	 quality	 (discussed	 in	 section	 2.4.2).	 Assay	artifacts	can	also	arise	due	to	the	presence	of	autofluorescent	molecules	in	screening	 libraries	 (Simeonov	 et	 al.,	 2008)	 and	 therefore	 the	 use	 of	 the	different	 applications	 listed	 in	 Table	 1,	 might	 be	 advantageous	 in	 drug	discovery	 screens	 (Chakraborty	 et	 al.,	 2009).	 	 Bioluminescence-based	methods	 are	 as	well	 common	 in	 screening	 assays,	 especially	 in	 reporter-gene	 assays.	 The	 mechanism	 and	 applications	 of	 bioluminescence	 are	reviewed	in	detail	in	section	2.5.		Technological	advances	have	resulted	in	cellular	imaging	being	used	in	high	content	 screening	 (HCS)	 at	 the	 early	 stages	 of	 drug	 discovery.	 The	advantages	of	HCS	are	 for	example,	 the	ability	 to	 choose	cell	populations,	the	immediate	detection	of	cytotoxic	effects	and	detection	of	certain	cellular	events	 that	 are	 difficult	 to	 track	 in	 other	ways,	 such	 as	 cell	motility.	The	drawbacks	are	the	vast	data	load	created,	the	limited	availability	of	specific	reagents	and	that	HC	assays	might	not	be	robust	enough	for	HTS	(Haney	et	al.	2006;	Bickle	2010).	
Table 3. Most often used detection technologies in HTS.
(Walters and Namchuk 2003; Wu and Doberstein 2006; Janzen 2014,)
Detection method  Assay format
Fluorescence Biochemical and cell-based
Fluorescence resonance energy transfer (FRET)
& Time-resolved (TRF , TR- FRET) Biochemical and cell-based
Bioluminescence Biochemical and cell-based
Bioluminescence resonance  energy Transfer (BRET) Biochemical and cell-based
AlphaScreen Biochemical and cell-based
Scintillation proximity assay (SPA) Biochemical
Fluorescence polarization (FP) Biochemical
Absorbance Biochemical and cell-based
Cell imaging High content screening
Label-free methods Biochemical and cell-based
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2.4.2. Assay	Development	for	HTS	
Assay	 optimization.	 Most	 HTS	 assays	 contain	 assay	 steps	 that	 are	simplified	from	bench	top	assays	by	removing	laborious	steps	(for	example	washing	 steps)	 and	 keeping	 reagent	 transfers	 to	 a	 minimum,	 to	 form	homogenous	 (mix-and-read)	 assays.	 If	 the	 assay	 is	 a	 novel	 one	 in	 HTS	context,	extensive	assay	optimization	and	validation	have	to	be	performed	before	implementation	of	the	assay	in	a	screening	campaign	(Macarron	and	Hertzberg	2011).	Most	steps	 in	 the	HTS	assay	optimization	phase	are	 the	same	 for	 biochemical	 and	 cell-based	 assays,	 for	 example;	 assay	 time	optimization,	 investigations	 of	 reagent	 stability,	 assay	 temperature	optimization,	estimation	of	assay	costs.		However,	 when	 implementing	 cell-based	 assays	 in	 HTS,	 there	 are	 some	specific	aspects	 that	need	 to	be	considered.	A	standard	operating	protocol	for	cell	culturing,	and	for	example	cryopreservation	of	the	cells	to	be	used	in	the	 assay,	 reduces	 the	 variability	 in	 experiments	 with	 different	 batches.	Depending	 on	 cell	 type	 and	 assay	 time,	 cell	 density	 in	 wells	 should	 be	optimized.	As	 the	compounds	need	 to	enter	 the	cells	 through	membranes,	an	evaluation	of	a	pre-incubation	time	should	be	considered.	Compounds	in	the	screening	libraries	are	commonly	stored	in	dimethyl	sulfoxide	(DMSO),	and	 DMSO	 is	 used	 as	 a	 vehicle	 in	 compound	 transfer	 to	 assay	 plate.	Therefore,	 the	 tolerability	of	 the	 assay	 to	DMSO	needs	 to	be	 investigated;	commonly	 concentrations	 between	 0	 to	 10%	 are	 tested.	 However,	 cell-based	 assays	 are	 more	 sensitive	 to	 DMSO,	 and	 can	 usually	 not	 tolerate	DMSO	 concentrations	 above	 1%	 (Hughes	 et	 al.,	 2011;	 Macarron	 and	Hertzberg	2011).		
Assay	 Miniaturization	 and	 Automation.	 The	 96-well	 plate	 is	 the	 most	common	 microtiter	 plate	 format	 used	 in	 low-	 and	 medium-throughput	screening,	 with	 a	 well	 volume	 of	 100-200	 µl.	 However,	 to	 increase	 the	throughput	and	to	lower	costs	most	HTS	screens	are	run	in	384-well	format.	The	well	volume	 in	 these	plates	can	 range	between	25-100	µl,	although	 a	typical	 screen	 in	 this	 format	 is	 usually	 around	 50	 µl	 per	 well.	 Industrial	screens	 also	 include	 the	 use	 of	 higher	 density	 plates;	 1536–well	 (1-10	µl/well)	 and	 even	ultra-high	density	plates	of	3456	wells	with	 a	working	volume	of	0.2-3	µl/well.	Robotic	 instruments	 are	usually	 involved	 in	HTS	
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screening	 campaigns	using	384-well	plates	 and	beyond.	 Screening	 can	be	semi-automated,	 using	 automated	 liquid	 handling	 robotic	 work	 stations	together	 with	 manual	 plate	 transfers	 and	 measurements.	 In	 a	 fully	automated	 screening	process	 liquid	handling	 and	plate	 transfers	between	different	workstations	can	be	performed	completely	using	a	robotic	system	(Mayr	 and	Bojanic	 2009;	Mannhold	 et	 al.,	 2006).	 Although,	 going	 from	 a	manual	 to	 an	 automated	 process	 is	 usually	 not	 straightforward,	 as	instrument	settings	need	to	be	carefully	assessed	and	adjusted	for	the	right	volumes,	speed,	height	and	positions	of	tips	and	plates	to	ensure	proper	and	reproducible	pipetting	of	reagents	to	assay	plates	(An	and	Tolliday	2010).	
Assay	performance	and	validation.	The	quality	determination	of	an	HTS	assay	 is	 driven	 by	 its	 primary	 goal;	 to	 identify	 active	 agents	 from	 large	collections	of	different	compounds.	Consequently,	a	HTS	assay	needs	to	be	robust,	sensitive,	 inexpensive	and	reproducible,	and	for	example	 in	case	of	miniaturization,	the	assay	signal	needs	to	be	maintained	at	a	suitable	 level	while	decreasing	the	volume	and	reagents.	Before	the	implementation	of	an	assay	in	a	screening	campaign,	the	quality	of	the	assay	needs	to	be	evaluated	and	also	monitored	during	the	screen.	An	assay	plate	generally	includes	maximum	signal	and	minimum	(background)	signal	 wells,	 which	 are	 the	 base	 in	 calculating	 statistical	 assay	 quality	parameters.	 The	 assay	 plates	 also	 contain	 positive	 control	 compounds,	usually	giving	the	wanted	response,	either	inhibiting	or	activating	the	target	for	 the	 measurement.	 The	 commonly	 used	 statistical	 parameters	 for	 the	evaluation	 of	 HTS	 assay	 performance	 are	 the	 Z’	 factor	 and	 signal	 to	background	(S/B)	parameter.	These	parameters	report	how	well	an	assay	works	by	assessing	the	separation	of	the	maximum	signal	and	background	signal	 as	 well	 as	 the	 variability	 by	 including	 the	 standard	 deviations	 of	signals	into	the	calculations	(formulas	for	these	parameters	are	given	in	the	material	and	methods	section).	The	signal	to	noise	(S/N)	parameter	is	often	included	 in	quality	calculations	although	seldom	used	 in	 the	evaluation	of	assay	performance	(Macarron	and	Hertzberg	2011).	Other	 factors	that	are	used	include	for	example	signal	window	and	coefficient	of	variation	(Inglese	et	al.,	2007).	
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Reproducibility	of	 the	assay	 is	also	 a	critical	 factor	when	 running	screens	over	a	long	period	of	time,	therefore	well-to-well,	plate-to-plate	and	day-to-day	variations	should	be	 investigated. The	 assay	 should	be	validated	with	known	inhibitors	and	a	pilot	screen	on	a	smaller	 library	containing	known	compound	should	be	ideally	performed	before	implementing	the	assay	in	a	larger	screening	campaign	(Iversen	et	al.,	2012).
2.4.3. Compound	Libraries	and	Other	Screening	Sources		The	progress	 in	synthetic	medicinal	chemistry	has	enabled	 the	generation	of	 large	 combinatorial	 chemistry	 compound	 libraries	 for	 screening	programs.	 The	 total	 amount	 of	 compounds	 in	 a	 library	 in	 the	pharmaceutical	 industry	 can	 be	 quite	 large,	 ranging	 from	 hundreds	 of	thousands	to	millions	(Kogej	et	al.,	2013).	Different	 libraries	 can	 be	 selected	 to	 be	 run	 in	 screening	 campaigns;	discovery	libraries	contain	usually	randomly	selected	compounds	with	high	molecular	diversity.	Focused	libraries	of	pre-selected	sets	can	be	used	when	certain	substructures	have	been	identified	to	be	involved	in	the	activity	for	
a	 specific	 target	 class	 (Hughes	 et	 al.,	2011;	Beresini	 et	 al.,	2014).	Besides	being	 synthetic,	 compounds	 originating	 from	 natural	 products	 (NPs),	 or	crude	 NP	 extracts	 are	 also	 used	 as	 a	 screening	 source	 (Harvey	 2007).	Natural	products	with	a	focus	on	antibacterial	drug	discovery	are	discussed	further	below.	
Natural	 products	 as	 a	 screening	 source.	 Natural	 product-derived	 (NP)	screening	 sources	 are	 compounds	 or	 extracts	 that	 can	 be	 obtained	 from	natural	 sources	 such	 as	 plants,	 microorganisms	 and	 animals.	 NP	 or	 NP-derived	compounds	have	been	an	important	source	for	the	pharmaceutical	industry,	where	 they	have	served	as	 leads	 in	drug	development	 (Baker	et	al.,	2007;	Harvey	2008;	Cragg	and	Newman	2013).	Natural	products	have	also	 been	 an	 important	 source	 in	 antibacterial	 drug	 discovery,	 as	 for	example	 penicillin	 was	 discovered	 from	 the	 fungus,	 Penicillium	 notatum,	and	many	of	the	following	antibiotics	were	also	discovered	by	screening	of	soil-derived	actinobacteria,	especially	 from	 the	Streptomyces	species	 (Dias	et	 al.,	2012;	Bérdy	2012).	The	most	 recent	discovery	of	 a	microorganism	derived	 new	 antibacterial	 compound	 termed	 teixobactin,	 active	 against	
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gram-positive	 bacteria,	 was	 accomplished	 by	 an	 in	 situ	 culture	 of	 soil-derived	bacteria	which	cannot	be	cultured	in	laboratory	conditions	(Ling	et	al.,	2015.)	
	According	 to	an	analysis	of	new	chemical	entities	(NCEs)	during	the	years	1981-2010,	74%	of	all	small-molecule	anti-infective	drugs	(bacterial,	fungal,	viral	and	parasitic)	are	natural	products	or	their	semisynthetic	derivatives	(Newman	and	Cragg	2012).	Besides	 infectious	diseases,	NPs	have	been	the	drug	 lead	 and	 inspiration	 for	 drugs	 in	 many	 different	 disease	 areas,	 for	example	dyslipidemia,	cancer,	Alzheimer’s	disease	and	diabetes	(Koehn	and	Carter	2005;	Newman	and	Cragg	2012).	For	example,	 the	LDL	cholesterol	lowering	drug	 lovastatin	 is	natural	product	derived,	originally	discovered	from	 a	 fermentation	 broth	 of	 the	 fungus	 Aspergillus	 terreus	 (Cragg	 and	Newman	2013).		
	Some	of	the	microbe-derived	antibiotics	have	also	antineoplastic	properties	and	 are	 used	 in	 oncology,	 such	 as	 agents	 belonging	 to	 the	 anthracycline,	bleomycin,	 actinomycin,	 mitomycin	 and	 staurosporine	 families.	 Thus,	natural	 products	 have	 also	 a	 big	 influence	 as	 leads	 in	 cancer	 drug	development.	Many	other	cancer	drugs	are	plant	derived;	some	of	the	most	well-known	 are	 vinblastine,	 vincristine	 and	 paclitaxel,	 originally	 isolated	from	different	sources	in	the	plant	kingdom	(da	Rocha	et	al	2001;	Cragg	and	Newman	2013;	Dias	et	al.,	2012).		
	Despite	 the	 many	 successful	 discoveries,	 the	 use	 of	 natural	 products	 in	bioactivity	screenings	has	been	in	decline.	Reasons	for	the	lowered	interest	can	be	addressed	to	the	facts	that	NPs	were	not	considered	to	be	compatible	with	 the	 HTS	 methods,	 and	 as	 natural	 products	 are	 often	 screened	 as	extracts,	 further	 identification	and	 isolation	steps	need	 to	be	 incorporated	into	 the	process.	Furthermore,	 the	 chemical	modification	of	very	complex	natural	products	 can	be	 a	 challenge	 in	 the	 lead	development	phase	 (Lam	2007).	The	process	of	drug	lead	discovery	from	natural	sources	is	shown	in	(Fig.	4).	
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Figure 4. The process of discovery of active compounds from natural products.Nevertheless,	due	 to	 their	better	 steric	 complexity	with	 larger	number	of	chiral	centers,	natural	products	can	contribute	by	broadening	the	chemical	diversity	 in	drug	development	(Koehn	and	Carter	2005).	As	 there	are	still	many	unexplored	natural	sources,	such	as	plant	and	fungal	kingdom	and	the	marine	environment	(Cragg	and	Newman	2013;	Kiuru	et	al.,	2014),	natural	products	 as	 a	 source	 and	 innovation	 of	 novel	 biomedical	 compounds	continues	to	be	an	interesting	option	in	drug	discovery	settings	(Schmitt	et	al.,	2011).	
		
2.5. Bioluminescence	
2.5.1. Mechanisms		Bioluminescence	is	a	phenomenon	where	light	is	produced	by	a	biochemical	reaction	and	occurs	naturally	 in	some	specific	organisms,	such	as	 insects,	bacteria,	 fish,	 plants	 and	 marine	 invertebrates	 (Table	 4).	 The	 light	 is	produced	 by	 an	 enzyme	 catalyzed	 biochemical	 reaction,	 where	 a	 light-producing	 group	 of	 a	 substrate	 is	 excited	 into	 a	 high	 energy	 state,	 and	photons	are	emitted	upon	return	to	the	ground	state.	The	enzymes	can	be	categorized	into	luciferases	and	other	photoproteins	(Scott	et	al.,	2011).	The	bacterial	luciferase	proteins	are	heterodimeric	proteins	consisting	of	α	and	
β	 subunits	 encoded	 by	 the	 lux	 genes	 (luxA	 and	 luxB).	 Bacterial	bioluminescence	is	catalyzed	by	a	different	reaction:	
	FMNH2	+	RCHO	+	O2											 	 FMN	+	H2O	+	RCOOH	+	light		
A	reduced	flavin	mononucleotide	reacts	with	oxygen	and	at	the	second	step	with	 a	 long	 chain	 fatty	 aldehyde,	 which	 in	 bacteria	 is	 tetradecanal.	 	 The	synthesis	 of	 the	 aldehyde	 substrate	 needed	 for	 the	 bacterial	bioluminescence	 reaction	 is	 catalyzed	 by	 a	 multienzyme	 complex,	 which	reduces	 fatty	 acids	 to	 aldehydes.	The	 complex	 consists	 of	 three	 proteins;	reductase,	 transferase	 and	 a	 synthetase.	 These	 three	 polypeptides	 are	
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encoded	by	the	genes	lux	C,	lux	and	luxE.		In	bacteria	all	the	enzymes	reside	in	 an	 operon	 (luxCDABE),	 consisting	 of	 all	 five	 genes	 coding	 for	 all	components	needed	to	produce	light	(Meighen	1991).	The	eukaryotic	bioluminescence	reactions	differ	from	the	prokaryotic	ones,	regarding	both	the	enzymes	and	the	substrates,	however	all	reactions	have	oxygen	 dependency	 in	 common.	 The	 most	 common	 eukaryotic	 luciferase	(Fluc)	is	a	monomeric	protein,	originating	from	the	firefly	(Photinus	pyralis).	The	eukaryotic	luciferase	is	dependent	on	ATP,	and	catalyzes	the	reaction:	
	D-luciferin	+	ATP	+	O2	 	 CO2	+	AMP	+	PPi	+	oxyluciferin	+	light	
	First	an	enzyme	bound	intermediate	is	formed	by	luciferin	and	ATP,	and	the	AMP-luciferyl	complex	is	then	oxidized,	and	the	generated	energy	produces	an	excited	state	of	oxyluciferin.	Upon	relaxation	of	 the	excited	state	to	 the	low	energy	state,	yellow-green	light	is	emitted	with	a	maximum	peak	at	560	nm	 (Scott	 et	 al.,	 2011).	 In	 addition,	 the	 photoproteins	 use	 another	mechanism.	For	example	aequorin	(Table	4),	consists	of	an	apoprotein	and	coelenterazine	as	chromophore.	The	bioluminescent	reaction	requires	Ca2+	binding,	 leading	 to	 a	 conformational	 change.	This	 allows	 the	 oxidation	 of	coelenterazine	to	an	unstable	intermediate,	which	releases	CO2,	resulting	in	excited	 state	 of	 coelenteramid,	 leading	 to	 light	 emission	 upon	 relaxation	(Fan	and	Wood	2007;	Scott	et	al.,	2011).	
	
2.5.2. Biotechnological	Applications	Luciferases	 from	 different	 sources	 (Table	 4)	 have	 been	 widely	 used	 in	bioassays.	For	example	detecting	the	presence	of	ATP	can	be	measured	by	the	firefly	luciferase	upon	addition	of	the	luciferin	substrate.	The	ATP	assay	has	 often	 been	 employed	 in	 viability	 (cytotoxicity)	 assays.	 Other	 assay	formats	measure	the	consumption	of	ATP,	employed	for	example	in	assays	for	kinases,	which	consume	ATP	upon	phosphorylation	of	their	substrates.	The	 photoproteins	 containing	 coelenterazine	 are	 commonly	 utilized	 in	different	signal	 transduction	 assays	detecting	Ca2+	 (Fan	 and	Wood	2007).	Bioluminescence	resonance	energy	transfer	can	be	used	 in	protein-protein	
Luciferase		
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interaction	 studies	 or	 in	 in-vivo	 monitoring	 of	 different	 biological	 events	(Roda	et	al.,	2004;	Hoshino	2009).		
	
Table 4. The most commonly used luciferases in biotechnological applications
Enzyme Type Source Substrate Emissionmax (nm)
Eukaryotic
Fluc Luciferase Firefly(photinus pyralis) D-Luciferin 560
Rluc Luciferase Sea Pansy(Renilla reniformis) Coelenterazine 485
Gluc Luciferase Marine copepod(Gaussia princeps) Coelenterazine 490
Aequorin photoprotein Jelly fish(Aequorea victoria) Coelenterazine 469
Bacterial
Lux Luciferase
Marine bacteria:
490
Vibrio fisheri and Vibrio
harvey FMNH2, RCHO
Terrestrial bacteria:
Photorhabdus
luminescens FMNH2, RCHO
	The	 luciferase	 genes	 can	be	 cloned	 into	 a	vector	 and	build	 reporter	 gene	systems	which	are	popular	applications	in	drug	discovery	screenings.	Using	bioluminescence	 as	 an	 assay	detection	method	 can	offer	 advantages	over	conventional	methods,	since	the	detection	 is	fast	and	sensitive,	and	can	be	used	with	 small-volume	 samples,	making	 it	 suitable	 for	HTS	 applications	(Roda	et	al.,	2003;	Fan	and	Wood	2007;	Michelini	et	al.,	2014.)	
	
2.5.3. Bioluminescent	Bacteria	As	Bioreporters		Cloning	 of	 the	 luciferase	 genes	 into	 non-luminescent	 bacteria	 using	 a	designed	promoter	acting	as	a	light	regulator	for	the	operon	can	be	used	to	create	 sensitive	 whole	 cell	 bioreporters	 used	 for	 example	 in	 assays	 for	detecting	 different	 analytes	 (Roda	 et	 al.,	 2004;	 Scott	 et	 al.,	 2011).	 	 The	reporter	 setup	 can	 be	 either	 an	 on	 (gain	 of	 signal)	 or	 off	 (loss	 of	 signal)	mechanism	 (Fig.	5).	Living	whole	cell	bioreporters	have	 for	example	been	extensively	 used	 as	 detecting	 microbes	 or	 antibiotic	 residues	 in	 food	(Virolainen	 et	 al.,	 2008	 and	 2012)	 as	 well	 as	 for	 detection	 of	 residue	compounds	in	environmental	samples	(Salste	et	al.,	2007).		
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Figure 5 .The principle of reporter bacteria. In on-systems the luciferase gene is under
control of a selective promoter or a regulatory gene, which in the presence of the analyte
or inducer turns on the transcription of luciferase genes, producing light (1). In the
opposite off-system, the bioluminescence genes can be either constitutively expressed or
first induced; with this system different analytes can be found by detection of a decrease
(2) in the light production (Figure adapted from Yagi 2007; Virolainen and Karp 2014).Different	 setups	 of	 bacterial	 whole	 cell	 bioreporters	 have	 also	 been	reported	 to	be	 suitable	 for	detection	of	 antibacterial	 agents	 (Galluzzi	 and	Karp	2006;	van	der	Meer	and	Belkin	2010).	Mycobacterium	smegmatis	was	one	of	the	earliest	bacterial	strains	to	be	used	for	the	expression	of	bacterial	luciferase	 genes	 (luxAB)	 in	 slow-growing	 bacteria	 (Andrew	 and	 Roberts	1993).	At	 the	same	 time,	Bacillus	subtilis	was	also	used	as	a	bacterial	host	for	the	expression	of	different	luciferase	genes	(Lampinen	et	al	1992).	There	have	been	several	other	reports	on	the	construction	of	many	mechanisms	of	action	based	bioreporter	of	different	bacterial	strains	(discussed	below).	
Gain	 of	 signal	 reporters.	 A	 mechanism-based	 bacterial	 assay	 using	recombinant	 bioluminescent	 bacteria	 was	 developed	 for	 the	 detection	 of	membranolytic	agents,	based	on	recombinant	strains	of	E.	coli	and	B.	subtilis	expressing	eukaryotic	luciferase	genes.	According	to	the	assay	principle,	the	presence	 of	 membranolytic	 agents	 increased	 the	 permeabilization	 of	 D-luciferin	into	the	cells,	leading	to	a	bioluminescent	signal	(Virta	et	al	1995).	Other	setups	have	also	used	the	on-design,	for	example	 in	reporter	strains	based	 on	 recombinant	 E.	 coli	 strains	 designed	 to	 detect	 compounds	belonging	to	a	specific	antibiotic	class.	Assay	designs	are	for	example	found	for	the	detection	of	β-lactam	resembling	compounds	(Valtonen	et	al.	2002),	
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tetracycline	 type	compounds	(Korpela	et	al	1998)	and	macrolides	class	of	compounds	(Mohrle	et	al.,	2007).		Firefly	 luciferase	 has	 for	 example	 been	 used	 to	 create	B.	subtilis	 reporter	strains	by	fusing	the	reporter	gene	to	different	kinds	of	specific	biomarker	promoters,	which	 are	 induced	by	 certain	 events.	 For	 example,	 a	 reporter	using	 stress-inducible	 promoter	 selective	 for	 fatty-acid	 pathway	 specific	inhibitors	has	been	developed	(Fisher	et	al.,	2004).	Other	studies	have	also	reported	 the	 construction	 of	 biomarker	 reporter	 luciferase	 genes	 for	 the	detection	 of	 for	 example	 inhibitors	 of	 DNA,	 RNA,	 protein	 and	 cell	 wall	synthesis	(Urban	et	al.,	2007).	Similar	systems	where	DNA	damage	sensitive	promoters	have	been	 fused	 to	bacterial	 luciferase	operons	have	also	been	used	 to	 construct	 reporter	 strains	 in	 E.	coli	(Vollmer	 et	 al.,	 1997),	 and	 P.	
aeruginosa	(Moir	et	al.,	2007)	for	the	detection	of	DNA	damaging	agents.	In	one	of	the	 latest	reports,	a	promoter	for	a	gene	shown	to	be	 induced	upon	inhibition	of	cell	wall	teichoic	acid	synthesis	was	fused	with	the	lux	genes	in	
a	 B.	 subtilis	 based	 reporter	 strain.	 In	 this	 work	 the	 assay	 was	 used	 in	 a	screen	targeting	cell-wall	inhibitors,	where	agar	had	been	solidified	into	the	wells	of	 a	96	well-plate,	with	a	kinetic	assay	setup	 for	19	h	(Czarny	et	al.,	2014).	
Loss	 of	 signal	 reporters.	 An	 example	 of	 an	 assay	 using	 an	 off-type	 of	system	 is	an	E.	coli	strain	using	a	heat	 inducible	system	designed	to	detect	chemicals	 affecting	 protein	 synthesis	 by	 inhibition	 of	 the	 bioluminescent	signal	 (Lampinen	 1995).	 	 In	 this	 setup	 the	 luxCDABE	 genes	 were	 clones	under	 phage	 lambda	 promoter,	 which	 is	 under	 control	 of	 a	 temperature	sensitive	 repressor.	 In	 this	 system,	 luciferase	 gene	 expression	 is	 first	induced	by	 a	heat-shock	 leading	 to	denaturation	of	 the	 repressor	protein.	Test	samples	are	thus	 incubated	with	the	bacterial	strains	and	compounds	that	decrease	 the	 luminescence	production	after	 induction	are	detected.	A	similar	heat	 inducible	design	was	used	 to	 construct	 an	E.	coli	bioreporter	strain	for	detection	of	DNA	replication	inhibitors.	The	bacterial	strain	holds	
a	luciferase	containing	plasmid	present	in	low	copy	number	in	normal	state	that	can	be	induced	with	a	heat-shock	to	replicate	into	high	copy	numbers.	Thus,	DNA	replication	 inhibitors	diminish	the	bioluminescent	signal	(Änkö	et	al.,	2002).	
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3. AIMS	OF	THE	STUDY	
The	 main	 aim	 of	 this	 thesis	 was	 to	 develop	 whole	 cell	 bioluminescence-based	high-throughput	screening	methods	for	antibacterial	drug	discovery	using	available	 recombinant	bacterial	strains.	There	 is	 a	vast	collection	of	recombinant	 bacterial	 strains	 that	 have	 been	 developed	 and	 shown	 to	function	as	whole	cell	bioreporters	for	the	detection	of	antibacterial	agents	(Galluzzi	and	Karp	2006).	However,	many	of	the	studies	have	focused	on	the	development	 and	 proof	 of	 principle	 and	 fewer	 studies	 have	 focused	 on	performing	 HTS	 using	 the	 recombinant	 strains.	 The	 aim	 was	 also	 to	implement	the	assays	in	screening	campaigns	of	compound	libraries	in	HTS	format	as	well	as	in	natural	product	extract	screening.The	specific	aims	were:	1) to	optimize,	validate,	miniaturize	and	automate	screening	assays	for	antibacterial	 drug	 discovery	 suitable	 for	 HTS	 using	 recombinant	bioluminescent	bacterial	strains	(I,	IV).	2) validate	 the	optimized	assay	 in	HTS	context	(I)	and	 implement	the	assay	in	a	screening	campaign	of	a	larger	compound	library	(II)	
3) evaluate	the	feasibility	of	the	developed	assays	for	the	screening	of	natural	product	extracts	and	in	bioactivity-guided	identification	and	isolation	of	active	fractions	from	natural	product	samples	(III,	IV)
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4. OVERVIEW	OF	MATERIAL	AND	METHODS	
This	 section	 provides	 an	 overview	 of	 the	 material	 and	 methods	 used,	further	details	of	the	experimental	procedures	and	methods	not	included	in	this	section	are	found	 in	the	original	publications	(I-IV).	A	summary	of	the	methods	and	the	references	to	publications	are	presented	in	Table	5.	
Table 5. Summary of methods used in the studies.
Method
Described
in
publication
Storage and culturing of E. coli K12 (pTetLux1) strain I, II
E. coli (pTetLux1) assay HTS protocol I, II
Compound pre-plating by acoustic dispensing I, II
ATCC strains and turbidometric growth inhibition assay II, III
Determination of compound solubility II
In vitro cytotoxicity assay against human hepatocytes (Huh-7) III
Virtual screening II
Assay based on E. coli K12 (pCGLS-11) III
Screening of in-house natural product library III
Extraction and fractionation of NP extract by HPLC IV
Identification of compound from active fraction by NMR IV
4.1. Bacterial	Strains	
4.1.1. Recombinant	Strains	and	Assays	In	this	work,	two	available	recombinant	bacterial	strains	were	used; E.	coli	K12	 (pTetLux1)	 and	 E.	 coli	 K12	 (pCGLS-11)	 which	 both	 contain	 the	luciferase	 operon	 (luxCDABE)	 originating	 from	 Photorhabdus	 luminescens.	This	 creates	 a	 self-illuminating	 system	 in	 the	 bacteria	 and	 enables	 the	bacteria	 to	 be	 used	 in	 reporter	 gene	 assays.	 The	 E.	 coli	 K12	 (pTetLux1)	strain	 contains	 the	 pTetLux1	 plasmid,	 where	 luciferase	 operon	 is	 placed	
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under	 the	 transcriptional	 control	 of	 a	 tetracycline	 responsive	 element.	 A	gene	 coding	 for	 a	 repressor	 protein	 is	 placed	 upstream	 of	 the	 luciferase	genes,	 repressing	 the	 expression	 of	 the	 luciferase	 genes	 in	 normal	 state	(Korpela	 et	 al.,	1998).	The	 expression	of	 luciferase	 genes	 in	 this	 strain	 is	induced	 by	 a	 very	 low	 concentration	 of	 tetracycline	 as	 the	 strain	 was	originally	 constructed	 and	 used	 for	 the	 detection	 of	 tetracycline	contaminants	(Kurittu	et	al.,	2000;	Virolainen	et	al.,	2008).	In	this	work	the	strain	 was	 used	 with	 a	 reverse	 loss	 of	 signal	 setup;	 first	 induction	 of	bioluminescence	 by	 sublethal	 amounts	 of	 tetracycline	 and	 then	measurement	 of	 the	 decrease	 in	 bioluminescence	 by	 antibacterial	compounds.	This	setup	has	been	previously	shown	 to	be	applicable	 in	 the	detection	 of	 antibacterial	 agents	 and	 to	 be	 sensitive	 in	 detecting	 in	particular	 transcriptional	 and	 translational	 inhibitors	 (Galluzzi	 and	 Karp	2003).	 In	 the	 other	 strain	 E.	 coli	 K12	 (pCGLS-11),	 the	 plasmid	 pCGLS-11	contains	 the	 luciferase	operon	 enabling	 constitutive	 luciferase	 expression	and	has	also	been	shown	to	be	suitable	for	detection	of	antibacterial	agents	(Vesterlund	et	al.,	2004).	The	recombinant	bacteria	were	initially	stored	long-term	in	15%	glycerol	at	
−80°C	or	as	lyophilized	stocks.	An	inoculum	from	the	long-term	stocks	was	used	to	initiate	cultures	for	the	preparation	of	single	dose	working	stocks	of	100	µl	(40%	glycerol)	stored	at	−20°C	and	used	within	3	weeks	in	the	assay	optimization	phases.	For	 the	HTS	screening	 in	studies	 I	and	 II,	 lyophilized	bacteria	were	used	as	the	inoculum	for	liquid	cultures.	Liquid	cultures	were	prepared	 by	 addition	 of	 50	 µl	 of	working	 stock	 or	 hydrated	 freeze-dried	bacteria	 to	 5	ml	 Luria-Bertani	 (LB)	 broth	 (Lennox)	 supplemented	with	 a	selective	agent	(ampicillin,	100	µg/ml).		The	 final	protocol	 used	 for	 the	 screening	 in	96-well	 and	HTS	 in	384-well	format	with	the	E.	coli	K12	(pTetlux1)	assay	is	presented	in	section	5.1.	The	assay	based	on	the	constitutive	strain	 in	96-well	format	described	 in	brief:	compounds	 and	 control	 antibiotics	 are	diluted	 into	LB	of	which	100	µl	 is	plated.	Afterwards,	100	µl	of	the	bacterial	dilution	in	LB	medium	is	added	to	the	wells	yielding	 a	 final	 inoculum	of	 approximately	5×105	CFU/well.	The	plate	 is	 incubated	 at	 37	 °C,	 250	 rpm;	 luminescence	 is	 measured	 at	 time	points	0	and	4	h.	
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4.1.2. Assays	Using	ATCC	Bacterial	Strains		The	bacterial	strains	used	to	determine	the	antibacterial	growth	inhibitory	activity	were	 control	 strains	of	American	Type	Culture	Collection	 (ATCC).	The	gram	negative	E.	coli	ATCC	25922	and	the	gram	positive	S.	aureus	ATCC	25923,	were	 from	Microbiologics	 Inc.	 (St.	 Cloud,	 MN,	USA).	Weekly	 slant	subcultures	 were	 prepared	 from	 a	 monthly	 culture	 (inoculated	 from	glycerol	 stocks	 stored	 at	 −80°C)	 and	 grown	 24	 h	 at	 37	 °C.	 From	 this,	 an	inoculum	was	used	to	start	liquid	cultures	that	were	incubated	for	16-24	h	at	37	 °C,	100	 rpm.	A	 fresh	dilution	of	 the	bacterial	culture	of	 appropriate	CFU	 concentration	 was	 made	 to	 be	 used	 as	 assay	 inoculum	 based	 on	previous	calibrations	between	CFU	and	absorbance	at	620	nm.	The	protocol	of	the	microdilution	assay	is	described	in	detail	in	publications	II	and	III.	
4.2. HTS	and	Screening	Sources	
4.2.1. Chemical	Libraries		The	 validation	 library	 used	 in	 study	 I	 was	 the	 Spectrum	 library	(MicroSource	 Discovery	 Systems	 Inc.,	 MA,	 USA),	 which	 is	 a	 collection	 of	2000	 compounds	 including	 various	 drugs	 (50%),	 pure	 compounds	 of	natural	 product	 origin	 (30%)	 and	 other	 bioactive	 compounds	 (20%).	 In	study	II,	a	set	of	10	240	compounds	from	the	ChemBridge	DIVERSet	library	(ChemBridge	Corporation,	San	Diego,	CA)	were	screened.	Both	compound	libraries	 were	 pre-plated	 into	 384-well	 plates	 (CulturePlate-384,	PerkinElmer	 Inc.,	 MA,	 USA)	 at	 30	 nl	 volumes	 using	 an	 acoustic	 liquid	handling	system	(Echo,	Labcyte	Inc.,	CA,	USA)	at	the	Institute	for	Molecular	Medicine	Finland. The	 ligand	based	 in	silico	screening	was	performed	on	a	virtual	 library	 of	 119	027	 compounds	 as	 well	 from	 the	 Institute	 for	Molecular	 Medicine	 Finland. The	 hits	 and	 further	 in	 silico	 selected	compounds	 were	 purchased	 from	 the	 original	 supplier	 (ChemBridge	Corporation,	San	Diego,	CA,	USA).	The	compound	libraries	were	screened	in	singlicate	 at	 10	 µM	 (0.5%	DMSO).	Miniaturization	 and	 automation	 of	 the	assay	in	384-well	plates	was	first	performed.	The	liquid	handling	in	the	HT	screen	 was	 performed	 using	 a	 Biomek	 FX	 liquid	 handling	 workstation	(Beckman	Coulter,	Fullerton,	CA,	USA).		
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4.2.2. Natural	Product	Extracts		The	 screening	 source	 in	 study	 III	 was	 an	 in-house	 library	 of	 136	 plant	extracts	 (divided	 into	 extracts	 from	 flower,	 stem,	 leaf	 and	 root	 parts),	originating	from	39	different	plant	species	that	grow	 in	Finland.	The	dried	extracts	were	dissolved	 into	DMSO	and	screened	 in	 the	primary	screen	at	50	and	100	µg/ml	(the	plant	species	and	experimental	details	are	described	in	III).	In	study	IV,	an	extract	based	on	the	culture	filtrate	of	a	Finnish	strain	FBCC310	 of	 the	 fungus	 Pycnoporus	 cinnabarinus	 (Jacq.)	 P.	 Karst	 was	obtained	 from	the	Fungal	Biotechnology	Culture	Collection,	Department	of	Food	and	Environmental	Sciences,	University	of	Helsinki.	The	 extract	was	further	 fractionated	 into	 96-well	 plates	 by	 coupling	 a	 fraction	 collector	(Gilson	FC	204,	Middleton	WI,	USA)	with	an	HPLC-UV	system	(PerkinElmer,	Norwalk	 CT,	 USA)	 and	 the	 fractions	 were	 screened	 with	 the	 E.	 coli	(pTetLux1)	 assay.	 A	 compound	was	 identified	using	NMR	 from	 the	 active	fraction	(experimental	details	are	found	in	IV).	
4.2.3. Parameters	for	Assay	Performance	Evaluations	The	optimal	assay	conditions	and	screening	performance	were	evaluated	by	known	assay	quality	parameters	such	as	Z’,	S/B	and	S/N.	The	formulas	used	for	calculating	the	parameters	used	in	this	study	are	originally	described	by	Zhang	et	al.,	1999	and	Bollini	et	al.,	2002.	
Z’ = 1 − (3 × ߪ୫ୟ୶	 + 3 × σ୫୧୬)|ߤ୫ୟ୶ − ߤ୫୧୬|S/B = μ୫ୟ୶
μ୫୧୬
S/N = (μ୫ୟ୶ − μ୫୧୬)
ඥ(ߪ୫ୟ୶ଶ + ߪ୫୧୬ଶ 	)
µ	 =	 mean	 of	 assay	 signal,	 max	 =	 maximum	 wells,	 min	 =	 minimum	(background)	wells,		σ	=	standard	deviation	of	signal.		The	Z’	value	should	be	between	0.5	and	1	for	an	acceptable	assay,	although	Z’	 >	 0.4	 is	 acceptable	 in	 some	 cases,	 such	 as	 cell-based	 assays.	 The	 S/B	should	 be	 >2,	 however	 there	 is	 no	 standard	 threshold	 value	 for	 the	 S/N	
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factor	 (Zhang	 et	 al.,	 1999;	 Inglese	 et	 al.,	 2007;	 Macarron	 and	 Hertzberg	2011).	
4.2.4. Analysis	of	Assay	Results		The	inhibitory	activity	of	test	compounds	in	the	inducible	E.	coli	(pTetLux1)	assay	was	calculated	as:	Inhibition	%	=	[1	−	(Ltest	–	Lmin)	/	(Lmax-L	min)]	×	100.	The	 inhibitions	using	 the	E.	coli	(pCGLS-11)	 assay	were	 calculated	by	 the	formula:	Inhibition	%	=	[1	−	(Ltest4h	−	Lmax	0h)	/	(Lmax	4h	−	Lmax	0h)]	×	100	In	 the	 equations	 above,	Ltest	 is	 the	 luminescence	value	 from	 an	 individual	test	compound	well.	Lmax	and	Lmin	are	the	mean	values	of	the	maximum	and	background	(non-induced)	wells.	The	 growth	 inhibitory	 activity	 in	 the	 broth	 microdilution	 assay	 was	calculated	 based	 on	 absorbance	 values	 and	 expressed	 as	 the	 percentage	inhibition	of	growth.Inhibition	%	=	[1	– (OD620	test	−	OD620	min	∕	OD620	max	−	OD620	min)]	×	100		OD620test	 is	 the	 absorbance	 at	620	nm	of	 a	 test	well	 and	OD620max	is	 the	absorbance	of	the	maximum	growth	control	at	a	given	time	point	(for	ex.	24	h).	OD620	min	is	the	background	values	(absorbance	values	at	time	0	h).	
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5. SUMMARY	OF	THE	MAIN	RESULTS		
In	 this	section,	a	summary	of	 the	main	results	 is	presented;	all	results	are	shown	 in	 detail	 in	 each	 original	 publication	 (I-IV)	 and	 in	 their	 online	supplements.	
5.1. Assay	Optimization	and	Miniaturization	for	HTS	(I)	As	the	expression	of	the	bioluminescent	genes	in	the	recombinant	strain	of	
E.	coli	K12	 (pTetLux1)	are	 inducible	and	 the	strain	has	been	shown	 to	be	sensitive	towards	certain	mechanisms	of	action,	this	strain	was	chosen	to	be	
a	 good	 option	 for	 developing	 a	 mechanism	 based	 miniaturized	 assay	suitable	for	HTS.	The	assay	optimization	was	started	 in	the	96-well	format	(200	µl	well	volume)	and	several	factors	were	 investigated	and	optimized,	such	as	the	inoculum	size	of	bacteria	in	the	wells,	pre-incubation	and	assay	incubation	 time,	 assay	 temperature	 and	DMSO	 tolerability	 (I,	Fig.	2).	The	assay	was	first	miniaturized	to	384-well	format	with	a	well	volume	of	50	µl.	Further	downscaling	of	the	well	volume	to	30	µl	was	also	evaluated	by	both	assay	 quality	 parameters	 and	 by	 the	 response	 of	 control	 antibiotics	 (I,	
Table	2).	Based	on	the	results,	final	assay	protocols	were	established	(Table	6).		The	miniaturized	and	automated	assay	was	validated	by	a	pilot-screen	of	a	chemical	 library	 containing	 known	 drugs	 and	 bioactive	 molecules.	 The	validation	screen	of	known	drugs	showed	 the	 feasibility	of	HTS	using	 the	assay	in	384-well	format	with	pre-plated	compounds	for	screening.		The	screening	 results	were	divided	 into	several	 inhibition	categories,	and	an	analysis	of	the	compounds	in	each	category	confirmed	that	the	majority	of	the	compounds	in	the	two	first	categories	(inhibitions	60-100%)	were	in	fact	 antibacterial	 compounds	 (I,	 Fig.	 5).	 In	 the	 third	 category,	 a	 larger	portion	of	other	types	of	drugs	were	also	 identified	as	active,	however	the	category	extended	down	to	30%	inhibition.	Analysis	of	the	fourth	category	
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confirmed	 that	 a	 hit	 threshold	 below	 30%	 would	 result	 in	 a	 high	 false	positive	 rate.	Further	analysis	of	 the	antibacterials	showed	 that	 the	assay	did	 lean	 towards	 detecting	 certain	 mechanism	 of	 action	 (I,	 Table	 3).	Transcription	 and	 translational	 inhibitors	were	 dominant,	 although	 some	DNA	 replication	 inhibitors	 were	 also	 identified,	 thus	 the	 mode	 of	 action	should	 be	 considered	 as	 indicatory	 a	 starting	 point	 for	 further	investigations,	 for	 identification	 of	 targets	 and	 ruling	 out	 unspecific	bactericidal	compounds.	
Table 6. Final protocols for E. coli (pTetLux1) assay in 96-well and 384-well format
Step Action (A) 96-well
(B) 384-
well Details
1 Plate samples and controls 100 µl 30 nl Diluted stocks from DMSO
2 Plate bacteria 50 µl 10 µl Dilution of bacteria in LB
3 Induce luminescence 50 µl 10 µl Tet-HCl addition
4 Pre-incubate plate 30 min 30 min 37 °C
5 Assay readout RLU RLU Luminescence
Additional notes
1 (A) Dilution of stocks in DMSO into LB: concentration should be 2x (1% DMSO)
to yield desired final conc. at 0.5% DMSO. (B) Direct pre-plating of DMSO stocks
into 384-well assay plates using an acoustic liquid handling system
2 (A) Inoculum 5×105 CFU/well (B) LB is added (20 µl background wells, 10 µl all
other wells) before addition of bacteria (5×104 CFU/well)
3 Tet-HCl is added to all wells except minimum (background) wells
4 Transfer plate to an incubator, use low agitation (A) ~ 250 rpm (B) minimalshaking
5 Measurement with either Victor
2 (A) or Varioskan flash (A, B). RLU = relative
light unit
	
5.2. HTS	of	a	Chemical	Library	(II)	After	the	proof-of-concept	screen,	the	developed	protocol	was	implemented	in	 HTS	 of	 a	 chemical	 library	 consisting	 of	 small	 molecules.	 The	 HTS	produced	eight	compounds	showing	over	50%	inhibition	in	the	assay.	After	hit	 identification,	 a	 hit	 enrichment	 was	 performed	 by	 in	 silico	 based	methods.	 Seven	 hit	 compounds	 (inhibition>60%,	 Table	 7)	 which	 were	
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available	 for	 purchase	 from	 the	 original	 supplier,	 were	 confirmed	 for	activity	 in	same	assay	setup	and	concentration	as	 in	the	primary	screen.	A	set	of	29	in	silico	selected	compounds	was	also	evaluated	similarly,	of	which	four	most	potential	were	selected	 together	with	 the	seven	hits	 for	 further	investigations	(Table	7).		The	selected	compounds	were	then	subjected	to	a	dose-response	evaluation	by	the	HTS	assay.	The	results	and	IC50	values	for	the	 inhibition	 in	 the	bioluminescence	based	antibacterial	assay	are	shown	in	Figure	6.	
Table 7. Structures and hit validation for the 11 selected compounds
Definition
Inhibition
in primary
HTS
Validation
Inhibition %
(± SD)a
Chemical structure Compoundnumber b
 Hit 1 86.9  65.9±1.8 6
Hit 2 78.0 91.3±2.9 5
Hit 3 63.8 76.2±0.5 4
Hit 4 63.6 95.1±0.4 7
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Hit 5 62.6 56.4±2.5 3
Hit 6 62.6 80.4±3.6 1
Hit 7 61.6 57.6±4.9 2
Chosen by
in silico
method
NA 36.7±2.2 8
Chosen by
in silico
method
NA 77.9±4.0 9
Chosen by
in silico
method
NA 68.6±1.9 10
Chosen by
in silico
method
NA 64.9±1.3 11
a interassay SD from two validation assays performed on different days. b Compound
number refers to numbering in publication II. NA = Not applicable.
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Figure 6. Dose-response and IC50 values for the selected compounds. The dose-
response experiments were performed using the E.coli (pTetLux1) assay in 384-well
format. The means and SDs of eight replicates were plotted in Origin Software for IC50
analysis.The	ability	of	the	compounds	to	inhibit	bacterial	growth	was	assessed	using	the	broth	dilution	method	based	on	turbidity.	The	bacteria	used	were	ATCC	strains	 commonly	 used	 as	 reference	 strains	 in	 clinical	 microbiology.	 A	gram-positive	 strain	was	 included	 in	 the	 studies,	 for	 primary	 assessment	whether	 the	 compounds	 could	 act	 as	 broad-spectrum	 (against	both	 gram	negative	 and	 positive)	 or	 as	 narrow-spectrum	 antibacterials.	 The	 growth	inhibitory	activity	on	these	strains	was	assessed	at	three	concentrations	at	
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two	time	points,	one	in	early	logarithmic	growth	phase	of	each	strain	and	an	endpoint	measurement	after	24	h	of	growth.	A	summary	of	the	 inhibitions	at	 100	 µM	 are	 presented	 in	 Table	 8.	 The	 inhibitions	 at	 the	 lower	concentrations	can	be	found	in	the	original	publication	(II,	Fig.	5).																		
Table 8. Summary of ATCC growth inhibition, solubility and in vitro human cell
toxicity of the 11 selected compounds
Com-
pound
number
E. coli ATCC 25922
(100 µM) a
S. aureus ATCC 25923
(100 µM) a Solubility
b Cytotoxicity c
Inhibition
% (4 h)
Inhibition
%  (24 h)
Inhibition
% (7 h)
 Inhibition %
(24 h) (µM in LB)
  (% at 100
µM)
1 55.1±1.9 6.1±0.7 94.3±4.0 30.1±7.4 100±50 7.8 ± 0.9
2 39.8±3.3 11.7±2.6 31.4±6.6 6±6.8 100±50 0
3 18.3±4.1 8.4±2.8 0±4.1 0±8.7 25±5 10.3±3.3
4 88.4±0.8 36.0±2.9 101±0.3 100.3±0.2  ≥200 61.0±1.0
5 93.5±7.8 23.2±1.9 100±13.0 100±3.3 62.5±12.5 98.6±0.6
6 8.9±1.7 4.4±1.6 20±7.3 0±5.8  25±5  15.0±0.9
7 32.5±3.2 5.5±3.3 13.8±12.3 0±13.7 25±5 0
8 32.7±14.5 14.3±1.2 0±11.9 0±14.1 87.5±12.5 28.4±2.5
9 60.9±0.6 2.1±0.9 96.7±0 46.2±5.8  ≥200 8.4±2.1
10 3.8±11.8 9.8±0.3 100±6.1 57.9±6.8 40±10 18.8±5.4
11 36.6±2.8 4.2±2.3 100±6.8 65.8±6.8 87.5±12.5 12.7±5.5
a Errors shown for inhibition % against bacterial growth are SD of three replicates.
b Calculated by taking the mean of the first conc. showing insolubility and the previous
concentration, error shown is the concentration × 0.5. c Cytotoxicity (average%±SD of
three replicates) towards Huh-7 cells.Based	on	the	results,	compounds	1,	4,	5	and	9-11	were	the	most	active.	The	bacterial	growth	 inhibitory	activities	of	 the	compounds	were	higher	 for	S.	
aureus	after	24	h,	for	example	compounds	4	and	5	completely	inhibited	the	growth	at	100	µM	(Table	8)	and	as	well	up	to	100%	and	80%	respectively,	at	50	µM	after	24	h	(II,	Fig.	5).	The	growth	inhibition	was	highest,	both	near	full	inhibition	for	these	compounds	in	the	early	logarithmic	phase	of	E.	coli	growth.	 Compounds	 1	 and	 9-11	 were	 fully	 inhibitory	 of	 early	 S.	 aureus	growth	 and	 moderate	 after	 24	 h.	 Compounds	 1,	 9	 and	 11	 were	 also	moderately	 inhibitory	 in	 early	 E.	 coli	 growth	 phase	 (Table	 8).	 The	
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compounds	 were	 also	 characterized	 for	 their	 solubility	 and	 human	 cell	cytotoxicity	(Table	8).	
5.3. Bioluminescence	Based	Assays	Implemented	in	
Natural	Product	Screening	(III,	IV)	In	 study	 III,	 a	 recombinant	 strain	 constitutively	 expressing	 the	 bacterial	luciferase,	 E.	 coli	 K12	 (pCGLS-11),	 was	 evaluated	 as	 a	 primary	 screening	tool	for	natural	product	extracts.	This	strain	was	utilized	in	a	pilot-screen	of	an	 in-house	plant	 extract	 library.	Altogether	136	plant	 extracts	were	 first	screened	using	the	E.	coli	(pCGLS-11)	assay	in	manual	96-well	format.	From	this	set,	15	extracts	showing	 inhibition	>	25%	at	100	µg/ml	were	selected	for	further	investigations	(III,	Table	2).	As	the	E.	coli	(pTetLux1)	assay	was	proved	to	be	suitable	for	HTS	of	small	molecule	compounds,	an	evaluation	of	employing	this	method	on	extracts	was	also	 included	 in	the	same	study.	This	assay	was	applied	on	the	set	of	extracts	selected	based	on	the	primary	screen	 (III,	 Fig.	 1B).	 The	 bacterial	 growth	 inhibitory	 activities	 of	 the	extracts	selected	by	the	bioluminescent	assay	were	first	assessed	at	a	high	concentration	against	the	ATCC	strains	of	E.	coli	and	S.	aureus	(III,	Table	2).	
A	 smaller	 set	of	 extracts	were	 tested	 at	multiple	 concentrations.	The	 leaf	and	root	extracts	of	Filipendula	ulmaria	and	the	flower	and	 leaf	extracts	of	
Calluna	 vulgaris,	 showed	 best	 inhibitory	 activity,	 particularly	 against	 S.	
aureus	growth.	In	 study	 IV,	 the	 inducible	 E.	 coli	 (pTetLux1)	 assay	 was	 used	 in	 the	investigation	of	the	antibacterial	activity	of	the	culture	filtrate	extract	from	
a	 polypore	 fungus,	 Pycnoporus	 cinnabarinus. The	 crude	 extract	 of	 the	 P.	
cinnabarinus	 strain	 had	 been	 previously	 identified	 to	 have	 antibacterial	properties.	However,	since	the	growth	inhibitory	assays	based	on	turbidity	measurements	 were	 not	 sensitive	 enough	 to	 identify	 activity	 in	 HPLC-fractions,	the	bioluminescence	based	antibacterial	assay	was	employed.		The	 activity	 in	 the	bioluminescence-based	 assay	was	 first	 investigated	on	the	crude	extract	from	a	culture	filtrate	of	the	fungus.	Activity	was	detected	and	based	on	the	results	from	dose-response	experiments	(Fig.	7),	the	IC50	value	 for	 the	crude	extract	was	determined	 to	be	100	µg/ml	 in	 the	E.	coli	(pTetLux1)	assay.	
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Figure 7. Dose-response profile of the fungal extract. The dose-response experiment
was performed using the E.coli (pTetLux1) assay. The values are the mean and SD of
four replicates. The IC50 value was calculated using Origin software (OriginLab Corp.,
Northampton, MA, USA)
	The	P.	cinnabarinus	culture	filtrate	extract	was	micro-fractioned	with	HPLC-UV	into	96-well	plates	and	the	186	fractions	obtained	were	screened	using	the	same	bioluminescent	assay.	Based	on	 the	results,	 the	activity	 found	 in	fractions	could	be	linked	to	a	UV	peak	in	the	HPLC	chromatogram	(IV,	Fig.	
1)	 after	 which	 isolation	 and	 identification	 of	 the	 active	 substance	 in	 the	peak	was	pursued.	As	a	conclusion	of	 this	study,	using	 the	bioluminescent	assay,	an	active	substance	was	isolated	from	the	fraction	and	identified	with	NMR	as	the	compound	phlebiarubrone,	a	known	fungal	pigment	compound	(IV	Fig.	2).		
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6. DISCUSSION		
6.1. Assay	Selection	and	Optimization	for	Antibacterial	
HTS	
	When	 choosing	 an	 assay	 format	 for	 HTS,	 several	 factors	 need	 to	 be	considered,	 such	 as	 the	 feasibility	 of	 miniaturization	 to	 higher	 density	plates.	 The	 most	 common	 antibacterial	 methods	 such	 as	 the	 broth	microdilution	and	the	resazurin	antibacterial	assays	are	usually	performed	in	96-well	plates.	Miniaturization	of	the	resazurin	assay	has	been	reported	in	384-well	format	 in	regular	mammalian	cytotoxicity	testing	(Shum	et	al.,	2008).	 However,	 the	 reports	 on	 the	 implementation	 of	 this	 method	 in	antimicrobial	HTS	 in	384	well	 formats	 are	mostly	 related	 to	 antiparasitic	and	 antifungal	 screening	 (Sykes	 and	 Avery	 2009;	 Monteiro	 et	 al.,	 2012).	Also,	these	methods	detect	viability	only	and	thus	do	not	give	any	indication	of	a	possible	mechanism	of	action.	Therefore	in	this	work,	an	approach	using	bioluminescent	based	assays	was	employed.	As	discussed	in	section	2.5.2,	ATP	quantification	can	be	used	for	viability	determinations	 and	 is	 commonly	used	 in	human	 cell	 cytotoxicity	assays.	This	approach	using	eukaryotic	 luciferase	has	also	been	evaluated	for	 the	 use	 in	 bacterial	 viability	 determination	 (Lafond	 et	 al.,	 2010).	The	ATP-based	assay	might	be	less	attractive	for	large	HT	screening	campaigns	as	 the	ATP	quantification	method	needs	additional	reagent	additions	after	the	 assay	 incubation	 time	 (lysis	 reagents	 and	 luciferin	 substrate).	 As	discussed	 in	 section	 2.4,	 an	 assay	 should	 be	 as	 simple	 as	 possible	 with	minimal	 assay	 steps	 and	 costs	 to	 be	 well-suited	 for	 HTS	 purposes.	Additionally,	 the	 ATP	 quantification	 approach	 is	 solely	 a	 viability	assessment	 method,	 compared	 to	 assays	 mechanism-based	 whole-cell	bacterial	bioreporters.		
A	 vast	 collection	 of	 different	 bioluminescent	 bacterial	 bioreporters	 have	been	described,	however	the	challenge	for	the	use	of	these	are	the	fact	that	the	 bioluminescent	 bacteria	 can	 differ	 in	many	ways	 (variables	 including	
Discussion	
54	
bacterial	host	 strain,	plasmid	 construction	 and	 luciferase	origin)	 and	 that	they	are	not	commercially	available.		As	the	antibiotic	discovery	of	antibacterials	for	gram-negative	bacteria	has	been	neglected,	two	recombinant	bioluminescent	bacterial	strains	based	on	
E.	coli	were	 chosen.	The	 E.	coli	 (pTetLux1)	 used	 in	 this	 thesis	 (I,	 II),	was	chosen	 as	 it	 has	 a	 mode	 of	 action	 based	 setup,	 shown	 previously	 to	 be	sensitive	 towards	 transcriptional	 and	 translational	 inhibitors.	 Another	advantage	 is	that	this	reporter	plasmid	strain	contains	the	whole	bacterial	luciferase	operon	luxCDABE	regulated	by	a	repressor,	creating	an	inducible	self-illuminating	system.	Other	bacterial	reporter	setups	for	detection	of	protein	synthesis	inhibitors	have	been	described	 (discussed	 in	section	2.5.3).	For	example,	comparing	the	E.	coli	(pTetLux1)	with	the	E.	coli	strain	using	the	heat-inducible	setup	(Lampinen	 et	 al.,	 1995),	 both	 methods	 measure	 the	 inhibition	 of	 the	reporter	signal.	The	induction	of	the	luminescence	in	E.	coli	(pTetLux1)	is	by	addition	of	an	inducer	compound.	Although	an	induction	by	physical	stimuli	instead	of	an	inducer	could	remove	a	 liquid	handling	step,	a	heat-inducible	system	 could	 easily	 create	 uneven	 induction	 of	 the	 assay	 plate	 in	 HT	screens.		The	 plate	 uniformity	 test	 of	 the	 E.	 coli	 (pTetLux1)	 assay	 in	 the	 assay	optimization	 phase	 (I)	 showed	 that	 the	 reproducibility	 of	 the	 reporter	signal	(high,	mid,	low)	was	good	in	384-well	format,	thus	suitable	for	use	in	HTS.	 The	 DMSO	 tolerance	 for	 the	 assay	 was	 concluded	 to	 be	 max	 1%,	although	ideally	should	be	≤0.5%,	which	is	quite	low,	although	similar	with	most	cell-based	assays.		Keeping	the	DMSO	concentration	in	the	assay	very	low	 can	become	 an	obstacle	 in	HTS	 since	 compound	 libraries	 are	usually	kept	in	DMSO.	Therefore	an	approach	of	using	pre-plated	compound	plates,	where	 the	 compounds	 were	 dispensed	 using	 an	 acoustic	 liquid	 handling	system,	was	evaluated.	This	enabled	to	keep	the	final	DMSO	content	low	and	as	well	 reducing	of	 the	needed	amount	of	 library	compounds	 to	nanoliter	volumes.	 	The	 pilot	 screen	 on	 the	 library	 of	 known	drugs	 and	 bioactives	confirmed	 the	 feasibility	 of	 using	 the	 assay	 in	 384-well	 format	with	 pre-plated	 compounds	 and	 validated	 the	 mechanism	 of	 action	 based	 assay	principle.		
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Due	to	smaller	size	of	the	natural	product	library	it	was	concluded	that	the	use	of	 the	miniaturized	 format	would	be	 redundant	and	 the	assay	 format	was	chosen	to	be	optimized	in	96-well	format.	
6.2. Implementation	and	Challenges	of	Bioluminescent	
Screening	Methods	
6.2.1. Interfering	Factors	in	HTS	Assays		The	 results	obtained	 from	 a	HT	screen	can	also	 include	 false	positive	and	false	negative	compounds.	False	positives	are	defined	as	compounds	giving	
a	 positive	 readout	 in	 the	 screening	 assay,	 but	 are	 however	 actually	 not	active	against	the	wanted	target	thus	not	giving	the	desired	biological	effect.	Assay	 artifacts	 can	 be	 caused	 in	 HTS	 assays	 by	 several	 ways	 and	 are	dependent	on	 the	assay	 format	as	well	as	on	 the	compounds	 tested.	False	positives	 in	HTS	are	often	due	to	different	types	of	compound	 interference	caused	 for	 example	 by;	 auto-fluorescent	 compounds,	 compound	aggregation,	 compounds	 interacting	 with	 assay	 components,	 light	quenching,	 light	 absorbing	 or	 scattering	 compounds,	 highly	 reactive	 and	oxidative	compounds	(Thorne	et	al.,	2010;	Pohjala	and	Tammela	2012).	The	challenge	in	using	reporter	gene	assays	is	the	possibility	of	identifying	actives	that	actually	are	compounds	that	interfere	with	the	reporter	protein,	for	 example	 the	 luciferase	 enzyme	 in	 bioluminescence	 based	 assays.	Therefore,	the	possibility	of	the	bioluminescent	assays	used	 in	studies	I-IV	to	 identify	 false	 positives	 (luciferase	 inhibitors)	 must	 be	 recognized	 in	further	 assessment	 of	 the	 obtained	 hit	 compounds.	 Purified	 eukaryotic	luciferases	are	commercially	available;	the	challenge	is	the	identification	of	bacterial	 luciferase	 inhibitors.	Possibly	 the	use	of	 another	 reporter	 strain	not	 used	 for	 antibacterial	 detection,	 incorporating	 bacterial	 luciferase	would	be	one	approach	to	test	for	false-positives.	
	In	 turn,	 cell-based	 assays	 might	 identify	 compounds	 having	 general	cytotoxic	properties	that	cause	trouble	in	further	drug	development	phases	
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(Crisman	 et	 al	 2007;	 Thorne	 et	 al.,	 2010).	 For	 example	 in	 study	 II,	 hit	number	 2	 (compound	 5)	 from	 the	 HT	 screen	 was	 found	 to	 display	 high	cytotoxic	properties	towards	human	Huh-7	cells	(Table	8).	
A	false	negative	is	a	compound	that	possesses	the	desired	biological	activity	sought,	but	is	identified	as	a	less	active	or	inactive	in	a	screening	assay.	For	example,	problems	in	compound	solubility	in	DMSO	or	in	assay	medium	can	lead	to	the	fact	that	interesting	compounds	might	be	missed	already	in	the	screening	 phase	 or	 cause	 incorrect	 assessment	 of	 a	 compound’s	 actual	biological	activity	(Di	and	Kerns	2006).		The	 limitations	caused	by	compound	 insolubility	could	be	seen	 in	study	II.	Visual	 observation	 during	 the	 sample	 dilution	 process	 for	 the	 bacterial	growth	inhibitory	assay	in	study	II	indicated	that	compound	solubility	could	be	a	possible	reason	behind	the	 low	antibacterial	activity	noticed	for	some	of	the	hits	identified	in	the	HT	screen.	The	compound	solubility	assessment	confirmed	the	solubility	issues	for	some	of	the	compounds	(Table	8).			
6.2.2. Challenges	in	Screening	Natural	Products		Screening	 natural	 products	 can	 also	 entail	 several	 obstacles.	 It	 can	 be	difficult	to	 integrate	natural	products	 into	HTS	assays	as	NP	screening	can	be	 performed	 either	 using	 crude	 extracts,	 a	 mixture	 of	 purified	 natural	products	 or	 purified	 compounds	 with	 known	 structures	 (Harvey	 2007;	Koehn	and	Carter	2005).	The	assays	 intended	for	the	two	first	alternatives	need	 to	 be	 sensitive	 enough	 to	 detect	 active	 compounds	 present	 in	 low	concentrations	within	 for	 example	 crude	 extracts.	The	 amount	 of	 extract	available	can	also	be	limited.	Therefore,	a	screening	assay	that	is	amenable	for	miniaturization	would	be	beneficial,	leading	to	savings	in	the	amount	of	extract	 needed	 (Fallarero	 et	 al.,	 2014).	 The	 feasibility	 of	 using	 a	bioluminescence-based	antibacterial	assay	in	medium-throughput	format	of	natural	product	libraries	was	for	example	demonstrated	in	study	III,	where	
a	library	of	136	plant	extracts	was	screened.	The	benefit	of	the	sensitivity	of	the	method	was	also	demonstrated	in	study	IV,	where	the	assay	was	used	to	screen	 a	 fractionated	 sample	 that	would	not	have	been	possible	with	 the	broth	microdilution	method.	The	yield	of	 the	 isolated	compound	 from	 the	active	 fraction	was	 enough	 for	 compound	 identification	 studies,	 however	
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unfortunately	 not	 enough	 for	 further	 biological	 experiments	 using	 the	standard	methods.	As	 natural	 product	 extracts	 are	 often	 screened	 at	 higher	 concentrations,	assay	 artifacts	 in	 screening	 assays	 can	 also	 be	 a	 challenge.	 For	 example,	some	natural	products	can	behave	 like	aggregators.	Auto-fluorescent,	very	colourful	 compounds	 and	 light	 absorbing	 compounds	 can	 also	 cause	problems	 in	 for	example	absorbance	and	 fluorescence	based	assays,	often	employed	in	antibacterial	screening	(Pohjala	and	Tammela	2012;	Fallarero	et	 al	 2014;	 Butler	 et	 al.	 2014).	 For	 example,	 the	 plant	 extract	 library	selected	 for	study	 III,	contained	extracts	 that	were	highly	colourful	at	 the	higher	concentrations,	compared	to	the	extract	used	in	study	IV,	which	was	nearly	colourless	(based	on	visual	observations).	Coloured	 compounds	 can	 reduce	 the	 transmission	 of	 light	 through	 the	solution	which	is	a	different	phenomenon	than	quenchers	of	fluorescence	or	bioluminescence	created	by	an	excited	state	of	a	molecule	(Comley	2003).	Thus,	 bioluminescence-based	 antibacterial	 assays	 might	 be	 less	 prone	 to	assay	interference	compared	to	assays	that	rely	on	turbidity	measurements.	However,	NPs	can	contain	compounds	that	can	quench	the	activated	state	of	
a	 fluorescent	 or	 chemiluminescent	 molecule,	 also	 leading	 to	 assay	interference	 (Comley	 2003),	 and	 similarly	 to	 pure	 chemical	 compounds,	there	 is	 a	 possibility	 that	 natural	 product	 extracts	 may	 contain	 reporter	enzyme	interfering	agents.	
6.2.3. Active	Compounds	Identified	by	the	Reporter	Assays	After	 confirmation	 of	 the	 hits	 from	 the	 HTS	 of	 the	 chemical	 library	 and	evaluations	of	the		in	silico	chosen	compounds,	11	compounds	were	further	evaluated	for	their	growth	inhibitory	properties	on	ATCC	strains,	solubility	and	in	vitro	human	cell	cytotoxicity.		The	growth	inhibitory	properties	of	the	compounds	were	promising	at	 the	early	 logarithmic	phase;	however	after	24	 h	 the	growth	 inhibitory	activities	were	decreased.	As	discussed	above,	low	compound	solubility	in	the	assay	medium	was	shown	to	be	a	potential	reason	 for	 this.	 	The	most	 active	 growth	 inhibitory	 compounds	 against	 S.	
aureus	growth	were	concluded	to	compounds	4	and	5	(original	HTS	hits	2	and	3).	
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	After	considering	all	 factors	 (cytoxicity,	solubility,	structural	novelty),	 the	
in	silico	chosen	compounds	9-11	were	concluded	to	be	the	most	interesting	compounds.	Even	 though	displaying	moderate	growth	 inhibitory	activities	against	S.	aureus,	 the	compounds	were	 found	 to	have	greater	novelty	and	lower	in	vitro	human	cell	toxicity	than	the	more	active	compounds	4	and	5.	By	 screening	 the	HPLC-fractions	of	P.	 cinnabarinus	 culture	 filtrate	 extract	using	 the	 bioreporter	 assay,	 a	 compound	 was	 isolated	 from	 the	 active	fraction.	 The	 compound	 was	 identified	 to	 be	 phlebiarubrone,	 a	 known	fungal	compound,	which	has	been	previously	 isolated	 from	 the	cultures	of	other	 fungal	species.	The	compound	has	been	shown	 to	have	antibacterial	properties	 against	 bacterial	 species	 of	 Acinetobacter	 and	 Bacillus	 (Anke,	1984).	 This	 confirms	 the	 sensitivity	 of	 the	 bioreporter	 assay	 to	 identify	compounds	with	antibacterial	properties	present	in	fractionated	extracts.
6.3. Conclusions	and	Future	Prospects	The	 rapid	 induction	 of	 luciferase	 expression	 and	 the	 setup	 allowing	 the	option	 to	 include	 non-inducible	 bacteria	 as	 background	 controls	 within	each	 assay	 plate	 in	 the	 assay	 based	 on	 E.	 coli	 (pTetLux1),	 resulted	 in	excellent	detection	of	known	antibacterial	agents	in	a	short	assay	time	of	90	min.	 Additionally	 this	 assay	 adds	 another	 dimension	 to	 the	 activity	profiling;	 rapid	 detection	 of	 antibacterial	 activity	 and	 first	 indication	 of	mechanism	 of	 action	 (study	 I).	 The	 assay	 was	 well	 amenable	 for	 further	miniaturization	 and	 automation	 for	 HTS,	 and	 antibacterial	 compounds	could	be	detected	in	HTS	of	chemical	libraries	in	384-well	format	(study	II).	This	 assay	 was	 successfully	 also	 used	 in	 screening	 of	 natural	 product	extracts	manually	in	96-well	format	(study	III).		As	 the	 constitutive	 strain	 uses	 a	 system	 where	 light	 is	 produced	continuously,	 the	 luminescence	 thus	 increases	with	 the	 bacterial	 density.	Using	this	setup	most	likely	allows	detection	of	compounds	with	a	broader	mechanism	 of	 action	 compared	 to	 the	 other	 strain.	The	 screen	 of	 the	 in-house	natural	product	library	demonstrated	the	suitability	for	medium	and	low	throughput	screening	of	NP	extracts	in	96-well	format.		
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Compared	to	the	E.	coli	(pTetLux1)	assay,	the	E.	coli	(pCGLS-11)	assay	time	for	 this	strain	was	 longer	 (4	h).	The	 longer	 incubation	 time	 is	needed	 for	this	assay	 to	obtain	 a	 reasonable	signal	window	between	 the	background	and	 the	end-point	measurement	since	using	 this	setup,	 the	background	 is	defined	 at	 time	 zero.	 The	 96-well	 format	 with	 agitation	 was	 a	 suitable	format	for	the	E.	coli	(pCGLS-11)	assay.	However,	the	feasibility	of	this	assay	for	screening	 in	384-well	plates	 is	something	that	could	be	 investigated	 in	the	future.		In	 conclusion,	 the	developed	bioluminescent	 assays	 as	primary	 screening	tools	are	time-saving	(2/4h	compared	to	24	h	in	conventional	methods)	as	well	 as	 resource	 and	 labour	 saving	 methods	 suitable	 for	 detection	 of	antibacterial	compounds	 in	HTS	 format.	Based	on	 the	 results	 in	study	 III,	the	 amount	 of	 extract	 can	 be	 saved	 for	 further	 studies	 by	 the	implementation	of	the	bioluminescence-based	assays	as	primary	screening	tools	in	antibacterial	natural	product	screening.	Study	IV	also	demonstrated	that	by	using	the	bioluminescent	assay,	identification	of	active	fractions	was	possible	 and	 advantageous	 in	 the	 cases	 where	 the	 turbidometric	 growth	inhibition	method	 is	not	sensitive	enough	to	detect	activity	 in	fractionated	samples.		As	discussed	 in	section	2.4,	primary	screening	hits	need	to	be	followed	up	with	one	or	more	orthogonal	assays	 to	rule	out	 false	positives.	 In	study	 II	and	III,	 the	96-well	microdilution	method	was	a	 feasible	orthogonal	assay	for	 the	 follow	up	of	 small	number	of	 compounds/extracts.	For	 future	HT	screenings,	 inclusion	 of	 one	 or	more	 orthogonal	 assays	 is	 recommended,	although	depending	on	the	amount	of	hits	obtained,	it	would	also	be	a	good	idea	to	develop	a	counter	screen	for	bacterial	luciferase	inhibitors.	In	 study	 II,	 the	HTS	 screen	 integrated	with	 in	silico	based	hit	 enrichment	and	hit	 follow	up	was	demonstrated	as	a	successful	screening	strategy	 for	antibacterial	drug	discovery.	Further	 investigations,	 for	example	structure	activity	 studies	 of	 the	 most	 interesting	 compounds	 identified	 in	 study	 II	could	be	pursued.	 In	 future	screens,	computational	methods	could	also	be	included	 for	 early	 identification	 of	 possible	 assay	 false	 positives	 such	 as	luciferase	enzyme	inhibitors	and	other	frequent	hitters.		
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